

# **Maywufa Company Ltd. and Subsidiaries**

**Consolidated Financial Statements for the  
Six Months Ended June 30, 2025 and 2024 and  
Independent Auditors' Review Report**

## **INDEPENDENT AUDITORS' REVIEW REPORT**

The Board of Directors and Shareholders  
Maywufa Company Ltd.

### **Introduction**

We have reviewed the accompanying consolidated balance sheets of Maywufa Company and its subsidiaries (collectively, the "Group") as of June 30, 2025 and 2024, the related consolidated statements of comprehensive income for the three months ended June 30, 2025 and 2024 and for the six months ended June 30, 2025 and 2024, the consolidated statements of changes in equity and cash flows for the six months then ended, and the related notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the "consolidated financial statements"). Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

### **Scope of Review**

We conducted our reviews in accordance with the Standards on Review Engagements of the Republic of China 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### **Conclusion**

Based on our reviews and the report of other auditors (refer to the other matter paragraph), nothing has come to our attention that caused us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as of June 30, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the six months ended June 30, 2025 and 2024 in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

## Other Matter

We did not review the financial statements of PhytoHealth Corporation, AmCad BioMed Corporation, and BroadSound Corporation accounted for using the equity method as of June 30, 2025 and 2024, but such statements were reviewed by other auditors. Our conclusion, insofar as it relates to the amounts of investments accounted for using the equity method and other comprehensive income included in the consolidated financial statements for these investees, is based solely on the reports of other auditors. According to the reports of other auditors as of June 30, 2025 and 2024, the amounts of the investments accounted for using the equity method of Maywufa Group were NT\$500,091 thousand and NT\$506,531 thousand, respectively, both representing 16% of the consolidated total assets; for the six months ended June 30, 2025 and 2024, the amounts of investments accounted for using the equity method - losses recognized by Maywufa Group were NT\$(8,880) thousand and NT\$(10,461) thousand, respectively, representing (7%) and (8%), respectively, of the consolidated total profit before income tax.

The engagement partners on the reviews resulting in this independent auditors' review report are Hai-Yueh Huang and Cheng-Chuan Yu.

Deloitte & Touche  
Taipei, Taiwan  
Republic of China

August 13, 2025

### Notice to Readers

*The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally applied in the Republic of China.*

*For the convenience of readers, the independent auditors' review report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' review report and consolidated financial statements shall prevail.*

# MAYWUFA COMPANY LTD. AND SUBSIDIARIES

## CONSOLIDATED BALANCE SHEETS (In Thousands of New Taiwan Dollars)

ASSETS	June 30, 2025		December 31, 2024		June 30, 2024	
	Amount	%	Amount	%	Amount	%
<b>CURRENT ASSETS</b>						
Cash and cash equivalents (Note 6)	\$ 92,588	3	\$ 175,367	6	\$ 190,321	6
Financial assets at fair value through profit or loss (Note 7)	42,000	1	12,000	-	-	-
Notes receivable (Notes 8 and 22)	15,893	1	11,145	-	14,983	-
Accounts receivable (Notes 8, 22 and 29)	253,215	8	239,286	8	249,717	8
Other receivables (Notes 8 and 29)	2,289	-	1,889	-	3,952	-
Inventories (Note 9)	299,431	9	279,750	9	266,315	9
Prepayments	3,478	-	2,160	-	1,937	-
Other financial assets - current (Note 10)	530,136	16	418,120	13	493,590	16
Other current assets (Note 16)	733	-	380	-	2,095	-
Total current assets	<u>1,239,763</u>	<u>38</u>	<u>1,140,097</u>	<u>36</u>	<u>1,222,910</u>	<u>39</u>
<b>NON-CURRENT ASSETS</b>						
Financial assets at fair value through other comprehensive income - non-current (Note 12)	108,184	4	135,606	5	137,043	5
Investments accounted for using the equity method (Note 13)	502,434	16	512,968	16	508,883	16
Property, plant and equipment (Notes 14 and 30)	1,246,646	39	1,269,968	40	1,096,906	35
Right-of-use assets (Note 15)	3,366	-	4,255	-	2,366	-
Intangible assets	7,200	-	7,072	-	4,567	-
Deferred tax assets (Note 4)	36,894	1	31,669	1	33,019	1
Refundable deposits	5,306	-	5,163	-	5,546	-
Net defined benefit assets - non-current (Note 4)	71,999	2	71,508	2	59,925	2
Other non-current assets (Note 16)	385	-	-	-	57,751	2
Total non-current assets	<u>1,982,414</u>	<u>62</u>	<u>2,038,209</u>	<u>64</u>	<u>1,906,006</u>	<u>61</u>
<b>TOTAL</b>	<u>\$ 3,222,177</u>	<u>100</u>	<u>\$ 3,178,306</u>	<u>100</u>	<u>\$ 3,128,916</u>	<u>100</u>
<b>LIABILITIES AND EQUITY</b>						
<b>CURRENT LIABILITIES</b>						
Short-term borrowings (Note 17)	\$ -	-	\$ 35,000	1	\$ 35,000	1
Notes payable (Note 18)	40	-	10	-	295	-
Accounts payable (Notes 18 and 29)	72,155	2	96,398	3	84,430	3
Other payables (Note 19)	418,321	13	249,975	8	394,186	12
Current tax liabilities (Note 4)	34,013	1	27,100	1	33,524	1
Lease liabilities - current (Note 15)	1,829	-	1,818	-	807	-
Other current liabilities	24,017	1	22,255	1	22,879	1
Total current liabilities	<u>550,375</u>	<u>17</u>	<u>432,556</u>	<u>14</u>	<u>571,121</u>	<u>18</u>
<b>NON-CURRENT LIABILITIES</b>						
Long-term borrowings (Notes 17 and 30)	634,464	20	634,464	20	539,570	18
Deferred tax liabilities (Note 4)	4	-	18	-	5	-
Lease liabilities - non-current (Note 15)	1,611	-	2,504	-	1,611	-
Guarantee deposits (Note 29)	1,945	-	1,945	-	1,945	-
Total non-current liabilities	<u>638,024</u>	<u>20</u>	<u>638,931</u>	<u>20</u>	<u>543,131</u>	<u>18</u>
Total liabilities	<u>1,188,399</u>	<u>37</u>	<u>1,071,487</u>	<u>34</u>	<u>1,114,252</u>	<u>36</u>
<b>EQUITY ATTRIBUTABLE TO SHAREHOLDERS OF THE PARENT (Note 21)</b>						
Share capital - ordinary shares	1,329,152	41	1,329,152	42	1,329,152	42
Capital surplus	192,208	6	192,157	6	189,395	6
Retained earnings						
Legal reserve	233,894	7	214,672	6	214,672	7
Special reserve	62,362	2	89,821	3	89,821	3
Unappropriated earnings	312,385	10	343,379	11	255,991	8
Total retained earnings	608,641	19	647,872	20	560,484	18
Other equity	(96,223)	(3)	(62,362)	(2)	(64,367)	(2)
Total equity	<u>2,033,778</u>	<u>63</u>	<u>2,106,819</u>	<u>66</u>	<u>2,014,664</u>	<u>64</u>
<b>TOTAL</b>	<u>\$ 3,222,177</u>	<u>100</u>	<u>\$ 3,178,306</u>	<u>100</u>	<u>\$ 3,128,916</u>	<u>100</u>

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated August 13, 2025)

## MAYWUFA COMPANY LTD. AND SUBSIDIARIES

### CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME OR LOSS (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended June 30				For the Six Months Ended June 30			
	2025		2024		2025		2024	
	Amount	%	Amount	%	Amount	%	Amount	%
OPERATING REVENUE (Notes 22 and 29)	\$ 374,653	100	\$ 350,274	100	\$ 796,989	100	\$ 757,975	100
OPERATING COSTS (Notes 9, 23 and 29)	<u>137,461</u>	<u>37</u>	<u>125,339</u>	<u>35</u>	<u>287,259</u>	<u>36</u>	<u>263,181</u>	<u>35</u>
GROSS PROFIT	<u>237,192</u>	<u>63</u>	<u>224,935</u>	<u>65</u>	<u>509,730</u>	<u>64</u>	<u>494,794</u>	<u>65</u>
OPERATING EXPENSES (Notes 20, 23 and 29)								
Selling and marketing expenses	151,644	40	145,567	42	330,911	42	315,375	42
General and administrative expenses	25,123	7	29,456	8	51,600	6	55,833	7
Expected credit impairment loss (gain on reversal) (Note 8)	<u>(442)</u>	<u>-</u>	<u>(602)</u>	<u>-</u>	<u>243</u>	<u>-</u>	<u>175</u>	<u>-</u>
Total operating expenses	<u>176,325</u>	<u>47</u>	<u>174,421</u>	<u>50</u>	<u>382,754</u>	<u>48</u>	<u>371,383</u>	<u>49</u>
PROFIT FROM OPERATIONS	<u>60,867</u>	<u>16</u>	<u>50,514</u>	<u>15</u>	<u>126,976</u>	<u>16</u>	<u>123,411</u>	<u>16</u>
NON-OPERATING INCOME AND EXPENSES (Note 23)								
Interest income	2,315	1	2,514	-	4,194	-	4,332	-
Other revenue (Note 29)	9,880	3	9,837	3	13,061	2	12,810	2
Other gains and losses	594	-	128	-	897	-	432	-
Interest expense	(1,935)	(1)	(65)	-	(3,937)	(1)	(76)	-
Share of profit or loss of associates (Note 13)	<u>(4,473)</u>	<u>(1)</u>	<u>(4,121)</u>	<u>(1)</u>	<u>(8,866)</u>	<u>(1)</u>	<u>(10,464)</u>	<u>(1)</u>
Total non-operating income and expenses	<u>6,381</u>	<u>2</u>	<u>8,293</u>	<u>2</u>	<u>5,349</u>	<u>-</u>	<u>7,034</u>	<u>1</u>
PROFIT BEFORE INCOME TAX	67,248	18	58,807	17	132,325	16	130,445	17
INCOME TAX EXPENSE (Notes 4 and 24)	<u>14,784</u>	<u>4</u>	<u>11,810</u>	<u>4</u>	<u>26,788</u>	<u>3</u>	<u>25,613</u>	<u>3</u>
NET PROFIT	<u>52,464</u>	<u>14</u>	<u>46,997</u>	<u>13</u>	<u>105,537</u>	<u>13</u>	<u>104,832</u>	<u>14</u>

(Continued)

## MAYWUFA COMPANY LTD. AND SUBSIDIARIES

### CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME OR LOSS (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	For the Three Months Ended June 30				For the Six Months Ended June 30			
	2025		2024		2025		2024	
	Amount	%	Amount	%	Amount	%	Amount	%
OTHER COMPREHENSIVE INCOME (LOSS) (Notes 13 and 21)								
Items that will not be reclassified subsequently to profit or loss								
Unrealized gain (loss) on investments in equity instruments at fair value through other comprehensive income	\$ (14,773)	(4)	\$ 7,118	2	\$ (3,754)	-	\$ 9,938	1
Share of the other comprehensive income of associates accounted for using the equity method	(2,502)	(1)	(2,259)	-	(3,793)	(1)	11,711	2
Items that may be reclassified subsequently to profit and loss								
Exchange differences on translation of financial statements of foreign operations	(15,087)	(4)	1,190	-	(11,585)	(1)	3,805	-
Total other comprehensive income (loss) (net of income tax)	(32,362)	(9)	6,049	2	(19,132)	(2)	25,454	3
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	<u>\$ 20,102</u>	<u>5</u>	<u>\$ 53,046</u>	<u>15</u>	<u>\$ 86,405</u>	<u>11</u>	<u>\$ 130,286</u>	<u>17</u>
NET INCOME ATTRIBUTABLE TO:								
Shareholders of the parent	<u>\$ 52,464</u>	<u>14</u>	<u>\$ 46,997</u>	<u>13</u>	<u>\$ 105,537</u>	<u>13</u>	<u>\$ 104,832</u>	<u>14</u>
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:								
Shareholders of the parent	<u>\$ 20,102</u>	<u>5</u>	<u>\$ 53,046</u>	<u>15</u>	<u>\$ 86,405</u>	<u>11</u>	<u>\$ 130,286</u>	<u>17</u>
EARNINGS PER SHARE (Note 25)								
Basic	<u>\$ 0.39</u>		<u>\$ 0.35</u>		<u>\$ 0.79</u>		<u>\$ 0.79</u>	
Diluted	<u>\$ 0.39</u>		<u>\$ 0.35</u>		<u>\$ 0.79</u>		<u>\$ 0.79</u>	

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated August 13, 2025)

(Concluded)

**MAYWUFA COMPANY LTD. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY**  
(In Thousands of New Taiwan Dollars, Except Dividends Per Share)

	Share Capital (Note 21)	Capital Surplus (Note 21)	Retained Earnings (Note 21)			Other Equity (Note 21)		Total Equity
			Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translation of Financial Statements of Foreign Operations	Unrealized Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income	
BALANCE ON JANUARY 1, 2024	\$ 1,329,152	\$ 189,320	\$ 197,797	\$ 106,162	\$ 304,546	\$ (18,070)	\$ (71,751)	\$ 2,037,156
Appropriation of 2023 earnings								
Legal reserve	-	-	16,875	-	(16,875)	-	-	-
Special reserve	-	-	-	(16,341)	16,341	-	-	-
Cash dividends - NT\$1.15 per share	-	-	-	-	(152,853)	-	-	(152,853)
Changes in capital surplus from investments in associates accounted for using the equity method (Notes 13 and 21)	-	75	-	-	-	-	-	75
Net profit for the six months ended June 30, 2024	-	-	-	-	104,832	-	-	104,832
Other comprehensive income (loss) for the six months ended June 30, 2024	-	-	-	-	-	3,805	21,649	25,454
Total comprehensive income (loss) for the six months ended June 30, 2024	-	-	-	-	104,832	3,805	21,649	130,286
BALANCE ON JUNE 30, 2024	<u>\$ 1,329,152</u>	<u>\$ 189,395</u>	<u>\$ 214,672</u>	<u>\$ 89,821</u>	<u>\$ 255,991</u>	<u>\$ (14,265)</u>	<u>\$ (50,102)</u>	<u>\$ 2,014,664</u>
BALANCE ON JANUARY 1, 2025	\$ 1,329,152	\$ 192,157	\$ 214,672	\$ 89,821	\$ 343,379	\$ (13,199)	\$ (49,163)	\$ 2,106,819
Appropriation of 2024 earnings								
Legal reserve	-	-	19,222	-	(19,222)	-	-	-
Special reserve	-	-	-	(27,459)	27,459	-	-	-
Cash dividends - NT\$1.20 per share	-	-	-	-	(159,497)	-	-	(159,497)
Changes in capital surplus from investments in associates accounted for using the equity method (Notes 13 and 21)	-	51	-	-	-	-	-	51
Disposal of investments in equity instruments designated at fair value through other comprehensive income/disposal of investments in equity instruments designated at fair value through other comprehensive income by associates (Notes 13 and 21)	-	-	-	-	14,729	-	(14,729)	-
Net profit for the six months ended June 30, 2025	-	-	-	-	105,537	-	-	105,537
Other comprehensive income (loss) for the six months ended June 30, 2025	-	-	-	-	-	(11,585)	(7,547)	(19,132)
Total comprehensive income (loss) for the six months ended June 30, 2025	-	-	-	-	105,537	(11,585)	(7,547)	86,405
BALANCE ON JUNE 30, 2025	<u>\$ 1,329,152</u>	<u>\$ 192,208</u>	<u>\$ 233,894</u>	<u>\$ 62,362</u>	<u>\$ 312,385</u>	<u>\$ (24,784)</u>	<u>\$ (71,439)</u>	<u>\$ 2,033,778</u>

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated August 13, 2025)

# MAYWUFA COMPANY LTD. AND SUBSIDIARIES

## CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands of New Taiwan Dollars)

	For the Six Months Ended June 30	
	2025	2024
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before income tax	\$ 132,325	\$ 130,445
Adjustments for:		
Depreciation expenses	25,975	12,854
Amortization expenses	1,227	895
Expected credit impairment loss	243	175
Net gain on fair value changes of financial assets at fair value through profit or loss	(179)	(34)
Interest expense	3,937	76
Interest income	(4,194)	(4,332)
Dividend income	(6,821)	(5,116)
Share of loss of associates	8,866	10,464
Changes in operating assets and liabilities:		
Financial assets at fair value through profit or loss	(29,821)	34
Notes receivable	(4,796)	7,614
Accounts receivable	(14,124)	(23,699)
Other receivables	(152)	(690)
Inventories	(20,183)	(8,278)
Prepayments	(1,330)	(610)
Other current assets	(353)	(519)
Net defined benefit assets	(491)	(183)
Notes payable	30	170
Accounts payable	(24,243)	916
Other payables	10,808	28,395
Other current liabilities	1,815	(2,719)
Cash generated from operations	78,539	145,858
Interest paid	(3,907)	(2,751)
Income tax paid	(25,114)	(24,622)
Net cash generated from operating activities	<u>49,518</u>	<u>118,485</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Disposal of financial assets at fair value through other comprehensive income	23,668	-
Acquisition of long-term equity investments accounted for using the equity method	(2,074)	-
Payments for property, plant and equipment	(6,028)	(145,430)
Increase in refundable deposits	(149)	(210)
Payments for intangible assets	(1,355)	(825)
Increase in other financial assets	(116,736)	(98,460)
Increase in prepayments for equipment	(2,846)	(6,276)

(Continued)

# MAYWUFA COMPANY LTD. AND SUBSIDIARIES

## CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands of New Taiwan Dollars)

	For the Six Months Ended June 30	
	2025	2024
Interest received	\$ 3,946	\$ 3,997
Dividends received	<u>6,821</u>	<u>5,116</u>
Net cash used in investing activities	<u>(94,753)</u>	<u>(242,088)</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Increase in short-term borrowings	-	35,000
Decrease in short-term borrowings	(35,000)	-
Proceeds from long-term borrowings	-	101,677
Repayment of the principal portion of lease liabilities	<u>(882)</u>	<u>(3,255)</u>
Net cash (used in) generated from financing activities	<u>(35,882)</u>	<u>133,422</u>
EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH AND CASH EQUIVALENTS HELD IN FOREIGN CURRENCIES	<u>(1,662)</u>	<u>2,021</u>
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(82,779)	11,840
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	<u>175,367</u>	<u>178,481</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	<u>\$ 92,588</u>	<u>\$ 190,321</u>

The accompanying notes are an integral part of the consolidated financial statements.

(With Deloitte & Touche review report dated August 13, 2025)

(Concluded)

# MAYWUFA COMPANY LTD. AND SUBSIDIARIES

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 (In Thousands of New Taiwan Dollars, Unless Stated Otherwise)

---

### 1. GENERAL INFORMATION

Maywufa Company Ltd. (the “Company”), along with the Company-controlled subsidiaries (collectively known as the “Group”), was incorporated in the Republic of China (ROC) in October 1976. The Company’s Chinese name was changed on April 30, 1998. The Company’s shares have been listed on the Taiwan Stock Exchange (TWSE) since September 17, 2001.

The main businesses of the Company are as follows:

- a. Manufacturing, processing and distribution of all kinds of hairdressing products (cleaning agents) soap, wholesale trading and agency.
- b. Manufacturing, processing and distribution of all kinds of cosmetics (except highly toxic), wholesale trading and agency, and trading of various department stores (the cosmetics manufacturing and processing department is limited to the main products of the factory).
- c. Distribution, wholesale and retail trading of various beauty products, health products and sports equipment.
- d. Retail and wholesale business of health food such as vitamin pills and oral liquid nutrients.
- e. Trading, wholesale and retail of medical drugs and medical equipment.
- f. Wholesale and retail sales of food, baby products and general food products enriched with vitamins, amino acids and minerals.
- g. The consulting and analysis business managed by the Pharmaceutical Affairs Bureau.
- h. Warehousing.

The consolidated financial statements are presented in the Company’s functional currency, the New Taiwan dollar.

### 2. APPROVAL OF FINANCIAL STATEMENTS

The consolidated financial statements were approved by the Company’s board of directors on August 13, 2025.

### 3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS

- a. Initial application of the amendments to the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) (collectively, the “IFRS Accounting Standards”) endorsed and issued into effect by the Financial Supervisory Commission (FSC)

The initial application of the IFRS Accounting Standards endorsed and issued into effect by the FSC did not have a material impact on the Group’s accounting policies.

- b. The IFRS Accounting Standards endorsed by the FSC for application starting from 2026

<b>New, Amended and Revised Standards and Interpretations</b>	<b>Effective Date Announced by IASB</b>
Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”	January 1, 2026
Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”	January 1, 2026
Annual Improvements to IFRS Accounting Standards - Volume 11	January 1, 2026
IFRS 17 “Insurance Contracts”	January 1, 2023
Amendments to IFRS 17	January 1, 2023
Amendments to IFRS 17 “Initial Application of IFRS 17 and IFRS 9 - Comparative Information”	January 1, 2023

As of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the other impacts of the above amended standards and interpretations on the Group’s financial position and financial performance and will disclose the relevant impact when the assessment is completed.

- c. The IFRS Accounting Standards in issue but not yet endorsed and issued into effect by the FSC

<b>New, Amended and Revised Standards and Interpretations</b>	<b>Effective Date Announced by IASB (Note)</b>
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture”	To be determined by IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	January 1, 2027
IFRS 19 “Subsidiaries without Public Accountability: Disclosures”	January 1, 2027

Note: Unless stated otherwise, the above IFRS Accounting Standards are effective for annual reporting periods beginning on or after their respective effective dates.

IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 will supersede IAS 1 “Presentation of Financial Statements”. The main changes comprise:

- Items of income and expenses included in the statement of profit or loss shall be classified into the operating, investing, financing, income taxes and discontinued operations categories.
- The statement of profit or loss shall present totals and subtotals for operating profit or loss, profit or loss before financing and income taxes and profit or loss.
- Provides guidance to enhance the requirements of aggregation and disaggregation: The Group shall identify the assets, liabilities, equity, income, expenses and cash flows that arise from individual transactions or other events and shall classify and aggregate them into groups based on shared characteristics, so as to result in the presentation in the primary financial statements of line items that have at least one similar characteristic. The Group shall disaggregate items with dissimilar characteristics in the primary financial statements and in the notes. The Group labels items as “other” only if it cannot find a more informative label.

- Disclosures on Management-defined Performance Measures (MPMs): When in public communications outside financial statements and communicating to users of financial statements management's view of an aspect of the financial performance of the Group as a whole, the Group shall disclose related information about its MPMs in a single note to the financial statements, including the description of such measures, calculations, reconciliations to the subtotal or total specified by IFRS Accounting Standards and the income tax and non-controlling interests effects of related reconciliation items.

Except for the above impact, as of the date the consolidated financial statements were authorized for issue, the Group is continuously assessing the other impacts of the above amended standards and interpretations on the Group's consolidated financial position and consolidated financial performance and will disclose the relevant impact when the assessment is completed.

#### **4. SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION**

##### **a. Statement of compliance**

These interim consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IAS 34 "Interim Financial Reporting" as endorsed and issued into effect by the FSC. Disclosure information included in these interim consolidated financial statements is less than the disclosure information required in a complete set of annual consolidated financial statements.

##### **b. Basis of preparation**

The consolidated financial statements have been prepared on the historical cost basis except for financial instruments which are measured at fair value, and net defined benefit assets which are measured at the present value of the defined benefit obligation less the fair value of plan assets.

The fair value measurements, which are grouped into Levels 1 to 3 based on the degree to which the fair value measurement inputs are observable and based on the significance of the inputs to the fair value measurement in its entirety, are described as follows:

- 1) Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
- 2) Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for an or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- 3) Level 3 inputs are unobservable inputs for the asset or liability.

##### **c. Basis of consolidation**

The consolidated financial statements incorporate the consolidated financial statements of the Company and the entities controlled by the Company (i.e., its subsidiaries). All intra-group transactions, balances, income and expenses are eliminated in full upon consolidation. Total comprehensive income of subsidiaries is attributed to the owners of the Company.

Refer to Notes 11 and 34, Tables 2 and 3 for detailed information on subsidiaries (including percentages of ownership and main businesses).

d. Other material accounting policies

Except for the following, please refer to the consolidated financial statements for the year ended December 31, 2024.

1) Retirement benefits

Pension cost for an interim period is calculated on a year-to-date basis by using the actuarially determined pension cost rate at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant plan amendments, settlements, or other significant one-off events.

2) Income tax expense

Income tax expense represents the sum of the tax currently payable and deferred tax. Interim period income taxes are assessed on an annual basis and calculated by applying to an interim period's pre-tax income the tax rate that would be applicable to expected total annual earnings.

## 5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

Refer to the consolidated financial statements for the year ended December 31, 2024 for the material accounting judgments and key sources of estimation uncertainty.

## 6. CASH AND CASH EQUIVALENTS

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
Cash on hand and petty cash	\$ 120	\$ 120	\$ 120
Checking accounts and demand deposits	54,569	118,967	41,678
Cash equivalents			
Time deposits with original maturities of 3 months or less	32,990	56,280	73,230
Call deposits with original maturities of 3 months or less	<u>4,909</u>	<u>-</u>	<u>75,293</u>
	<u>\$ 92,588</u>	<u>\$ 175,367</u>	<u>\$ 190,321</u>

The market interest rate intervals of bank deposits at the end of the reporting period were as follows:

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
Bank deposits	0.05 % - 1.15 %	0.002 % - 1.15 %	0.05% - 1.45%
Time deposits with original maturities of 3 months or less	1.225%	1.225%	1.225% - 1.275%
Call deposits with original maturities of 3 months or less	1.2%	-	1.55%

## 7. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS

	June 30, 2025	December 31, 2024	June 30, 2024
<u>Current</u>			
Mutual funds	<u>\$ 42,000</u>	<u>\$ 12,000</u>	<u>\$ -</u>

## 8. NOTES RECEIVABLE, ACCOUNTS RECEIVABLE AND OTHER RECEIVABLES

	June 30, 2025	December 31, 2024	June 30, 2024
<u>Notes receivable</u>			
At amortized cost			
Gross carrying amount	\$ 16,054	\$ 11,258	\$ 15,135
Less: Allowance for impairment loss	<u>(161)</u>	<u>(113)</u>	<u>(152)</u>
	<u>\$ 15,893</u>	<u>\$ 11,145</u>	<u>\$ 14,983</u>
<u>Accounts receivable</u>			
At amortized cost			
Gross carrying amount	\$ 255,850	\$ 241,702	\$ 251,065
Less: Allowance for impairment loss	<u>(2,635)</u>	<u>(2,440)</u>	<u>(2,545)</u>
	<u>253,215</u>	<u>239,262</u>	<u>248,520</u>
Accounts receivable from related parties (Note 29)	-	24	1,197
Less: Allowance for impairment loss	<u>-</u>	<u>-</u>	<u>-</u>
	<u>-</u>	<u>24</u>	<u>1,197</u>
	<u>\$ 253,215</u>	<u>\$ 239,286</u>	<u>\$ 249,717</u>
<u>Other receivables</u>			
Interest	\$ 518	\$ 270	\$ 589
Other	<u>67</u>	<u>50</u>	<u>560</u>
	585	320	1,149
Other receivables from related parties (Note 29)	<u>1,704</u>	<u>1,569</u>	<u>2,803</u>
	<u>\$ 2,289</u>	<u>\$ 1,889</u>	<u>\$ 3,952</u>

### a. Notes receivable

The average credit period of sales of goods is 1-7 months. No interest is charged on notes receivable. In order to minimize credit risk, the management of the Group has delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. The Group transacts with a large number of unrelated customers; therefore, credit risk is not highly concentrated. In this regard, the management believes the Group's credit risk is significantly reduced.

The Group measures the loss allowance for notes receivable at an amount equal to lifetime ECLs. The expected credit losses on notes receivable are estimated using a provision matrix by reference to the past default records of the customer and the customer's current financial position. As the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished according to the Group's different customer base.

The Group writes off a note receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery. For notes receivable that have been written off, the Group continues to engage in enforcement activity to attempt to recover the receivables due. Where recoveries are made, these are recognized in profit or loss.

The following table details the loss allowance of notes receivable based on the Group's provision matrix:

June 30, 2025

	<b>Not Past Due</b>	<b>1 to 60 Days Past Due</b>	<b>61 to 90 Days Past Due</b>	<b>91 to 120 Days Past Due</b>	<b>Over 120 Days Past Due</b>	<b>Total</b>
Expected credit loss rate	1%	-	-	-	-	
Gross carrying amount	\$ 16,054	\$ -	\$ -	\$ -	\$ -	\$ 16,054
Loss allowance (Lifetime ECLs)	<u>(161)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(161)</u>
Amortized cost	<u>\$ 15,893</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 15,893</u>

December 31, 2024

	<b>Not Past Due</b>	<b>1 to 60 Days Past Due</b>	<b>61 to 90 Days Past Due</b>	<b>91 to 120 Days Past Due</b>	<b>Over 120 Days Past Due</b>	<b>Total</b>
Expected credit loss rate	1%	-	-	-	-	
Gross carrying amount	\$ 11,258	\$ -	\$ -	\$ -	\$ -	\$ 11,258
Loss allowance (Lifetime ECLs)	<u>(113)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(113)</u>
Amortized cost	<u>\$ 11,145</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 11,145</u>

June 30, 2024

	<b>Not Past Due</b>	<b>1 to 60 Days Past Due</b>	<b>61 to 90 Days Past Due</b>	<b>91 to 120 Days Past Due</b>	<b>Over 120 Days Past Due</b>	<b>Total</b>
Expected credit loss rate	1%	-	-	-	-	
Gross carrying amount	\$ 15,135	\$ -	\$ -	\$ -	\$ -	\$ 15,135
Loss allowance (Lifetime ECLs)	<u>(152)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(152)</u>
Amortized cost	<u>\$ 14,983</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 14,983</u>

The movements of the loss allowance of notes receivable were as follows:

	<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>
Balance on January 1	\$ 113	\$ 227
Add: Provision	48	-
Less: Reversal	<u>-</u>	<u>(75)</u>
Balance on June 30	<u>\$ 161</u>	<u>\$ 152</u>

b. Accounts receivable

The average credit period of sales of goods is 1-7 months. No interest is charged on accounts receivable. In order to minimize credit risk, the management of the Group has delegated a team responsible for determining credit limits, credit approvals and other monitoring procedures to ensure that follow-up action is taken to recover overdue debts. The Group transacts with a large number of unrelated customers; therefore, credit risk is not highly concentrated. In this regard, the management believes the Group's credit risk was significantly reduced.

The Group measures the loss allowance for accounts receivable at an amount equal to lifetime ECLs. The expected credit losses on accounts receivable are estimated using a provision matrix prepared by reference to the past default records of the customer and the customer's current financial position. As the Group's historical credit loss experience does not show significantly different loss patterns for different customer segments, the provision for loss allowance based on past due status is not further distinguished according to the Group's different customer bases.

The Group writes off an account receivable when there is information indicating that the debtor is in severe financial difficulty and there is no realistic prospect of recovery, e.g. when the debtor has been placed under liquidation, or when the trade receivables are over 180 days past due, whichever occurs earlier. For accounts receivable that have been written off, the Group continues to engage in enforcement activity to attempt to recover the receivables due. Where recoveries are made, these are recognized in profit or loss.

The following table details the loss allowance of notes receivable based on the Group's provision matrix:

June 30, 2025

	<b>Not Past Due</b>	<b>1 to 60 Days Past Due</b>	<b>61 to 90 Days Past Due</b>	<b>91 to 120 Days Past Due</b>	<b>Over 120 Days Past Due</b>	<b>Total</b>
Expected credit loss rate	1%	1%	1%	1%	1%	
Gross carrying amount	\$ 254,008	\$ 1,721	\$ 112	\$ 6	\$ 3	\$ 255,850
Loss allowance (Lifetime ECLs)	<u>(2,617)</u>	<u>(17)</u>	<u>(1)</u>	<u>-</u>	<u>-</u>	<u>(2,635)</u>
Amortized cost	<u>\$ 251,391</u>	<u>\$ 1,704</u>	<u>\$ 111</u>	<u>\$ 6</u>	<u>\$ 3</u>	<u>\$ 253,215</u>

December 31, 2024

	Not Past Due	1 to 60 Days Past Due	61 to 90 Days Past Due	91 to 120 Days Past Due	Over 120 Days Past Due	Total
Expected credit loss rate	1%	1%-1.02%	-	-	-	
Gross carrying amount	\$ 222,500	\$ 19,226	\$ -	\$ -	\$ -	\$ 241,726
Loss allowance (Lifetime ECLs)	<u>(2,248)</u>	<u>(192)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(2,440)</u>
Amortized cost	<u>\$ 220,252</u>	<u>\$ 19,034</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 239,286</u>

June 30, 2024

	Not Past Due	1 to 60 Days Past Due	61 to 90 Days Past Due	91 to 120 Days Past Due	Over 120 Days Past Due	Total
Expected credit loss rate	1%	1%	1%	1%	1%	
Gross carrying amount	\$ 243,042	\$ 9,210	\$ 5	\$ 2	\$ 3	\$ 252,262
Loss allowance (Lifetime ECLs)	<u>(2,453)</u>	<u>(92)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(2,545)</u>
Amortized cost	<u>\$ 240,589</u>	<u>\$ 9,118</u>	<u>\$ 5</u>	<u>\$ 2</u>	<u>\$ 3</u>	<u>\$ 249,717</u>

The movements of the loss allowance of accounts receivable were as follows:

	For the Six Months Ended June 30	
	2025	2024
Balance on January 1	\$ 2,440	\$ 2,295
Add: Provision	<u>195</u>	<u>250</u>
Balance on June 30	<u>\$ 2,635</u>	<u>\$ 2,545</u>

c. Other receivables

The Group measures the loss allowance for other receivables at an amount equal to lifetime ECLs. The Group estimates the loss allowance by reference to the past default records of the customer and the customer's current financial position, and uses other publicly available financial information or its own trading records to rate the default risk of different receivables. As of June 30, 2025, December 31, 2024 and June 30, 2024, the management of the Group assessed other receivables with no expected credit losses.

**9. INVENTORIES**

	June 30, 2025	December 31, 2024	June 30, 2024
Commodities	\$ 71,393	\$ 68,181	\$ 72,624
Finished goods	135,960	125,605	97,716
Packaging materials	36,147	36,742	42,082
Raw materials	43,851	43,261	46,194
Work in progress	<u>12,080</u>	<u>5,961</u>	<u>7,699</u>
	<u>\$ 299,431</u>	<u>\$ 279,750</u>	<u>\$ 266,315</u>

The nature of the cost of goods sold is as follows:

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2025	2024	2025	2024
Cost of inventories sold	\$ 132,227	\$ 123,264	\$ 279,996	\$ 259,991
Inventory obsolescence loss	<u>5,234</u>	<u>2,075</u>	<u>7,263</u>	<u>3,190</u>
	<u>\$ 137,461</u>	<u>\$ 125,339</u>	<u>\$ 287,259</u>	<u>\$ 263,181</u>

## 10. OTHER FINANCIAL ASSETS - CURRENT

	June 30, 2025	December 31, 2024	June 30, 2024
Time deposits with original maturities of more than 3 months	<u>\$ 530,136</u>	<u>\$ 418,120</u>	<u>\$ 493,590</u>

The market intervals of time deposits with original maturities of more than 3 months in the bank at the end of the reporting period were as follows:

	June 30, 2025	December 31, 2024	June 30, 2024
Time deposits	1.285%-1.690%	1.285%-1.690%	1.285%-1.690%

## 11. SUBSIDIARIES

### Subsidiaries Included in the Consolidated Financial Statements

Investor	Investee	Nature of Activities	Percentage of Ownership (%)		
			June 30, 2025	December 31, 2024	June 30, 2024
Maywufa Company Ltd.	Maywufa Corporation (Samoa Maywufa)	Investment holdings	100.00	100.00	100.00
Maywufa Corporation (Samoa Maywufa)	Maywufa Hongkong Corporation Limited (Hong Kong Maywufa)	Investment holdings	100.00	100.00	100.00
Maywufa Hongkong Corporation Limited (Hong Kong Maywufa)	Maywufa Cosmetics (Shanghai) Co., Ltd. (Maywufa (Shanghai) Company)	Cosmetics and household goods wholesale	100.00	100.00	100.00

The main business risks of Samoa Maywufa and its subsidiaries are political risk and exchange rate risk due to changes in government regulations and cross-strait relations.

## 12. FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

	June 30, 2025	December 31, 2024	June 30, 2024
<u>Non-current</u>			
Domestic investments			
Listed shares	\$ 23,411	\$ 49,360	\$ 53,555
Unlisted shares	78,505	79,314	76,517
Foreign investments			
Unlisted shares	<u>6,268</u>	<u>6,932</u>	<u>6,971</u>
	<u>\$ 108,184</u>	<u>\$ 135,606</u>	<u>\$ 137,043</u>

Refer to Note 34 and Table 1 (Marketable Securities Held) for information relating to the investments in the table above.

Refer to Note 21(e) for information relating to financial assets at fair value through other comprehensive income.

These investments in equity instruments are held for strategic purposes. Accordingly, the management elected to designate these investments in equity instruments as at FVTOCI as they believe that recognizing short-term fluctuations in these investments' fair value in profit or loss would not be consistent with the Group's strategy of holding these investments for purposes.

The Group adjusted the portion of the investment and sold certain listed ordinary shares at the fair value of \$23,668 thousand, resulting in an unrealized gain of \$7,368 thousand in the related other equity - financial assets at fair value through other comprehensive income and loss transferred to retained earnings for the six months ended June 30, 2025.

## 13. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

	June 30, 2025	December 31, 2024	June 30, 2024
<u>Listed company</u>			
PhytoHealth Corporation	\$ 445,009	\$ 451,990	\$ 460,552
AmCad BioMed Corporation	33,477	35,763	23,254
<u>Unlisted company</u>			
Broadsound Corporation	21,605	22,886	22,725
Lu Te Na Company Limited	<u>2,343</u>	<u>2,329</u>	<u>2,352</u>
	<u>\$ 502,434</u>	<u>\$ 512,968</u>	<u>\$ 508,883</u>

The Group's percentage of ownership and voting rights in associates as of the balance sheet date were as follows:

Name of Company	June 30, 2025	December 31, 2024	June 30, 2024
PhytoHealth Corporation	17.76%	17.69%	17.69%
AmCad BioMed Corporation	6.31%	6.31%	6.52%
Broadsound Corporation	10.00%	10.00%	10.00%
Lu Te Na Company Limited	35.00%	35.00%	35.00%

The Group holds less than 20% of the shares of PhytoHealth Corporation, AmCad BioMed Corporation, and Broadsound Corporation, but obtained some directors of these companies; therefore, it has significant influence over these companies, which are all accounted for using the equity method.

Refer to Note 34 and Table 2 (Information on Investees) for more information on the investees.

For the six months ended June 30, 2025 and 2024, the Group's share of profit or loss in investments in associates accounted for using the equity method was as follows:

Name of Company	For the Six Months Ended June 30	
	2025	2024
PhytoHealth Corporation	\$ (5,620)	\$ (8,119)
AmCad BioMed Corporation	(1,979)	(1,743)
Broadsound Corporation	(1,281)	(599)
Lu Te Na Company Limited	<u>14</u>	<u>(3)</u>
	<u>\$ (8,866)</u>	<u>\$ (10,464)</u>

The liquidation of Lu Te Na Co. was approved in March 2025, and the dissolution registration has been completed with the municipal government. As of June 30, 2025, the liquidation has not yet been finalized.

The Group recognized an increase of \$51 thousand and \$76 thousand in capital surplus for the changes in other equity of the associates in proportion to its shareholding as of June 30, 2025 and 2024, respectively.

The Group recognized \$7,361 thousand of equity instruments measured at fair value through other comprehensive income for the six months ended June 30, 2025, based on the percentage of ownership of the associates, and the related other equity - unrealized gain was transferred to retained earnings.

As a result of the change in paid-in capital due to the exercise of employee stock options issued by the AmCad BioMed Corporation for the six months ended June 30, 2024, the Group's shareholding in AmCad BioMed Corporation was reduced to 6.52%, which resulted in a change in the net value of the Group's investment in the Company's net assets, and the capital surplus should be adjusted for an decrease of \$1 thousand. On July 24, 2024, AmCad BioMed Corporation set the base date for its capital increase and conducted a cash capital increase at a subscription price of NT\$23 per share. As the Group did not subscribe to the newly issued shares in proportion to its existing shareholding, its equity interest in AmCad BioMed Corporation was diluted, resulting in a decrease in the Group's shareholding ratio to 6.31% following the capital increase.

Share of the other comprehensive income (loss) of associates accounted for using the equity method is recognized based on the financial statements of each associate reviewed by accountants for the same period.

The information on the Group's associates is summarized as follows:

	<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>
The Group's share of:		
Loss from continuing operations	\$ (8,866)	\$ (10,464)
Other comprehensive income (loss)	<u>(3,793)</u>	<u>11,711</u>
Total comprehensive income (loss) for the period	<u>\$ (12,659)</u>	<u>\$ 1,247</u>

Information on the level 1 fair value of related companies with open market quotations is as follows:

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
PhytoHealth Corporation	<u>\$ 488,582</u>	<u>\$ 590,196</u>	<u>\$ 716,666</u>
AmCad BioMed Corporation	<u>\$ 65,318</u>	<u>\$ 89,288</u>	<u>\$ 95,876</u>

#### 14. PROPERTY, PLANT AND EQUIPMENT

	<b>Land</b>	<b>Buildings</b>	<b>Machinery and Equipment</b>	<b>Income- generating Equipment</b>	<b>Other Equipment</b>	<b>Construction in Progress</b>	<b>Total</b>
<u>Cost</u>							
Balance on January 1, 2025	\$ 293,932	\$ 1,076,495	\$ 136,997	\$ 19,233	\$ 1,708	\$ 1,348	\$ 1,529,713
Additions	-	-	-	226	-	3,887	4,113
Reclassification (Note)	-	4,929	1,744	873	150	(5,235)	2,461
Effects of foreign currency exchange differences	-	(10,502)	-	(12)	-	-	(10,514)
Balance on June 30, 2025	<u>\$ 293,932</u>	<u>\$ 1,070,922</u>	<u>\$ 138,741</u>	<u>\$ 20,320</u>	<u>\$ 1,858</u>	<u>\$ -</u>	<u>\$ 1,525,773</u>
<u>Accumulated depreciation and impairment</u>							
Balance on January 1, 2025	\$ -	\$ (231,138)	\$ (26,107)	\$ (2,189)	\$ (311)	\$ -	\$ (259,745)
Depreciation expenses	-	(17,766)	(5,776)	(1,361)	(183)	-	(25,086)
Effects of foreign currency exchange differences	-	5,697	-	7	-	-	5,704
Balance on June 30, 2025	<u>\$ -</u>	<u>\$ (243,207)</u>	<u>\$ (31,883)</u>	<u>\$ (3,543)</u>	<u>\$ (494)</u>	<u>\$ -</u>	<u>\$ (279,127)</u>
Carrying amount on December 31, 2024 and January 1, 2025	<u>\$ 293,932</u>	<u>\$ 845,357</u>	<u>\$ 110,890</u>	<u>\$ 17,044</u>	<u>\$ 1,397</u>	<u>\$ 1,348</u>	<u>\$ 1,269,968</u>
Carrying amount on June 30, 2025	<u>\$ 293,932</u>	<u>\$ 827,715</u>	<u>\$ 106,858</u>	<u>\$ 16,777</u>	<u>\$ 1,364</u>	<u>\$ -</u>	<u>\$ 1,246,646</u>
<u>Cost</u>							
Balance on January 1, 2024	\$ 293,932	\$ 389,928	\$ 51,767	\$ 2,515	\$ 2,181	\$ 472,125	\$ 1,212,448
Additions	-	609	143	1,200	1,708	141,770	145,430
Reclassification (Note)	-	2,238	933	-	-	-	3,171
Effects of foreign currency exchange differences	-	3,338	-	3	-	-	3,341
Balance on June 30, 2024	<u>\$ 293,932</u>	<u>\$ 396,113</u>	<u>\$ 52,843</u>	<u>\$ 3,718</u>	<u>\$ 3,889</u>	<u>\$ 613,895</u>	<u>\$ 1,364,390</u>

(Continued)

	Land	Buildings	Machinery and Equipment	Income-generating Equipment	Other Equipment	Construction in Progress	Total
<u>Accumulated depreciation and impairment</u>							
Balance on January 1, 2024	\$ -	\$ (213,815)	\$ (38,498)	\$ (1,776)	\$ (2,156)	\$ -	\$ (256,245)
Depreciation expenses	-	(7,193)	(2,011)	(238)	(165)	-	(9,607)
Effects of foreign currency exchange differences	-	(1,630)	-	(2)	-	-	(1,632)
Balance on June 30, 2024	<u>\$ -</u>	<u>\$ (222,638)</u>	<u>\$ (40,509)</u>	<u>\$ (2,016)</u>	<u>\$ (2,321)</u>	<u>\$ -</u>	<u>\$ (267,484)</u>
Carrying amount on June 30, 2024	<u>\$ 293,932</u>	<u>\$ 173,475</u>	<u>\$ 12,334</u>	<u>\$ 1,702</u>	<u>\$ 1,568</u>	<u>\$ 613,895</u>	<u>\$ 1,096,906</u>

(Concluded)

Note: The reclassification is transferred from the prepayments for equipment.

There was no indication that property, plant and equipment was impaired, so the Group did not perform an impairment test for the six months ended June 30, 2025 and 2024.

Property, plant and equipment of the Group are depreciated on a straight-line basis over their estimated useful lives as follows:

<b>Buildings</b>	
Main building	34-61 years
Mechanical and electrical engineering	5-20 years
Decoration engineering	5-15 years
Machinery equipment	3-15 years
Income-generating equipment	3-10 years
Other equipment	5 years

The property and plant pledged as collateral for bank borrowings are set out in Note 30.

## 15. LEASE ARRANGEMENTS

### a. Right-of-use assets

	June 30, 2025	December 31, 2024	June 30, 2024	
<u>Carrying amount</u>				
Transportation equipment	<u>\$ 3,366</u>	<u>\$ 4,255</u>	<u>\$ 2,366</u>	
	<u>For the Three Months Ended June 30</u>		<u>For the Six Months Ended June 30</u>	
	2025	2024	2025	2024
Additions to right-of-use assets			<u>\$ -</u>	<u>\$ 1,025</u>
Depreciation charge for right-of-use assets				
Buildings	\$ -	\$ 1,079	\$ -	\$ 2,698
Transportation equipment	<u>444</u>	<u>158</u>	<u>889</u>	<u>549</u>
	<u>\$ 444</u>	<u>\$ 1,237</u>	<u>\$ 889</u>	<u>\$ 3,247</u>

Except for the aforementioned recognized depreciation, the Group did not have significant sublease or impairment of right-of-use assets for the six months ended June 30, 2025 and 2024.

b. Lease liabilities

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
<u>Carrying amounts</u>			
Current	<u>\$ 1,829</u>	<u>\$ 1,818</u>	<u>\$ 807</u>
Non-current	<u>\$ 1,611</u>	<u>\$ 2,504</u>	<u>\$ 1,611</u>

Range of discount rate for lease liabilities was as follows:

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
Buildings	-	1.079%	1.079%
Transportation equipment	1.079%-1.211%	1.079%-1.211%	1.079%-1.211%

c. Material leasing activities and terms

The Group leases transportation equipment for general operating activities for the period of 3 to 5 years.

At the end of the lease term, the Group does not have bargain purchase options to acquire the above lease properties.

d. Other lease information

	<b>For the Three Months Ended June 30</b>		<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Expenses relating to short-term leases	<u>\$ 587</u>	<u>\$ 532</u>	<u>\$ 1,161</u>	<u>\$ 1,224</u>
Expenses relating to low-value asset leases	<u>\$ 87</u>	<u>\$ 80</u>	<u>\$ 174</u>	<u>\$ 167</u>
Total cash outflow for leases			<u>\$ (2,240)</u>	<u>\$ (4,663)</u>

The Group elected to apply the exemption from recognition to certain leases of office equipment that qualify as short-term leases of buildings and construction and that qualify as low-value leases of assets, and not to recognize the related right-of-use assets and lease liabilities for these leases.

## 16. OTHER ASSETS

	June 30, 2025	December 31, 2024	June 30, 2024
<u>Current</u>			
Temporary payments	\$ <u>733</u>	\$ <u>380</u>	\$ <u>2,095</u>
<u>Non-current</u>			
Prepayments for equipment	\$ <u>385</u>	\$ <u>-</u>	\$ <u>57,751</u>

## 17. BORROWINGS

### a. Short-term borrowings

	June 30, 2025	December 31, 2024	June 30, 2024
Unsecured borrowings			
Line of credit borrowings	\$ <u>-</u>	\$ <u>35,000</u>	\$ <u>35,000</u>

The effective interest rates for bank loans were 0.5% as of December 31, 2024 and June 30, 2024.

### b. Long-term borrowings

	June 30, 2025	December 31, 2024	June 30, 2024
Secured borrowings (Note 30)			
Bank loans	\$ <u>634,464</u>	\$ <u>634,464</u>	\$ <u>539,570</u>

Bank loan's floating rates of the bank loans, which the Group used to build a factory, are calculated monthly on the balance of the principal, with interest paid monthly for the first 66 months and the principal repayable in equal monthly installments from the 67th month (February 2028) onward, at an effective interest rate of 0.68% to 1.21% per annum, and the loan period is eight years. The Group used the loan to build a factory.

## 18. NOTES PAYABLE AND ACCOUNTS PAYABLE

	June 30, 2025	December 31, 2024	June 30, 2024
<u>Notes payable</u>			
Operating	\$ <u>40</u>	\$ <u>10</u>	\$ <u>295</u>
<u>Accounts payable</u>			
Operating	\$ 48,170	\$ 76,670	\$ 55,404
Related parties (Note 29)	<u>23,985</u>	<u>19,728</u>	<u>29,026</u>
	\$ <u>72,155</u>	\$ <u>96,398</u>	\$ <u>84,430</u>

## Accounts Payable

The Group has a financial risk management policy to ensure that all accounts payable are repaid within the prearranged credit period, which ranges from one to six months.

### 19. OTHER PAYABLES

	June 30, 2025	December 31, 2024	June 30, 2024
Dividends payable	\$ 159,497	\$ -	\$ 152,853
Payables for promotion fee	93,792	83,419	86,150
Payables for advertising fee	76,065	69,153	62,787
Payables for salaries and bonuses	52,016	55,463	44,018
Others	<u>36,951</u>	<u>41,940</u>	<u>48,378</u>
	<u>\$ 418,321</u>	<u>\$ 249,975</u>	<u>\$ 394,186</u>

### 20. RETIREMENT BENEFIT PLANS

The pension expenses of the defined benefit plan were calculated based on the actuarially determined pension cost rate on December 31, 2024 and 2023. An analysis by function of the pension expense was as follows:

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2025	2024	2025	2024
Operating expenses	<u>\$ (246)</u>	<u>\$ (92)</u>	<u>\$ (491)</u>	<u>\$ (183)</u>

### 21. EQUITY

#### a. Share capital

##### Ordinary shares

	June 30, 2025	December 31, 2024	June 30, 2024
Shares authorized (in thousands of shares)	<u>300,000</u>	<u>300,000</u>	<u>300,000</u>
Shares authorized	<u>\$ 3,000,000</u>	<u>\$ 3,000,000</u>	<u>\$ 3,000,000</u>
Shares issued and fully paid (in thousands of shares)	<u>132,915</u>	<u>132,915</u>	<u>132,915</u>
Shares issued and fully paid	<u>\$ 1,329,152</u>	<u>\$ 1,329,152</u>	<u>\$ 1,329,152</u>

b. Capital surplus

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
May be used to offset a deficit, distributed as cash dividends, or transferred to share capital (Note 1)			
Issuance of ordinary shares	\$ 161,940	\$ 161,940	\$ 161,940
<u>May only be used to offset a deficit</u>			
Share of changes in capital surplus of associates	29,193	29,142	26,380
Dividends unclaimed by shareholders (Note 2)	<u>1,075</u>	<u>1,075</u>	<u>1,075</u>
	<u>\$ 192,208</u>	<u>\$ 192,157</u>	<u>\$ 189,395</u>

Note 1: Such capital surplus may be used to offset a deficit; in addition, when the Company has no deficit, such capital surplus may be distributed as cash dividends or transferred to share capital (limited to a certain percentage of the Company's capital surplus and once a year).

Note 2: According to the letter Jingshangzi No. 10602420200 issued by the Ministry of Economic Affairs on September 21, 2017, unclaimed dividends should be recognized as capital reserves.

A reconciliation of the carrying amount at the beginning and at the end for the six months ended June 30, 2025 and 2024 for each class of capital surplus was as follows:

	<b>Issuance of Ordinary Shares</b>	<b>Changes in Capital Surplus from Investment in Associates Accounted for Using the Equity Method</b>	<b>Dividends Unclaimed by Shareholders</b>	<b>Total</b>
Balance on January 1, 2025	\$ 161,940	\$ 29,142	\$ 1,075	\$ 192,157
Changes in capital surplus from investments in associates accounted for using the equity method	<u>-</u>	<u>51</u>	<u>-</u>	<u>51</u>
Balance on June 30, 2025	<u>\$ 161,940</u>	<u>\$ 29,193</u>	<u>\$ 1,075</u>	<u>\$ 192,208</u>
Balance on January 1, 2024	\$ 161,940	\$ 26,305	\$ 1,075	\$ 189,320
Changes in capital surplus from investments in associates accounted for using the equity method	<u>-</u>	<u>75</u>	<u>-</u>	<u>75</u>
Balance on June 30, 2024	<u>\$ 161,940</u>	<u>\$ 26,380</u>	<u>\$ 1,075</u>	<u>\$ 189,395</u>

c. Retained earnings and dividends policy

Under the dividends policy as set forth in the Articles, where the Company made a profit in a fiscal year, the profit shall be first utilized for paying taxes, offsetting losses of previous years, setting aside as legal reserve 10% of the remaining profit, setting aside or reversing a special reserve in accordance with the laws and regulations, and then any remaining profit together with any undistributed retained earnings at least used 10% by the Company's board of directors as the basis for proposing a distribution plan, which should be resolved in the shareholders' meeting for the distribution of dividends and bonuses to shareholders. For the policies on the distribution of compensation of employees and remuneration of directors after the amendment, refer to compensation of employees and remuneration of directors in Note 23 (g).

Appropriation of earnings to the legal reserve shall be made until the legal reserve equals the Company's paid-in capital. The legal reserve may be used to offset deficits. If the Company has no deficit and the legal reserve has exceeded 25% of the Company's paid-in capital, the excess may be transferred to capital or distributed in cash.

When the Company makes a provision for the special surplus reserve for the net reduction of other benefits accumulated in the previous period, it only makes a provision for the undistributed surplus of the previous period.

The appropriations of earnings for 2024 and 2023 that had been resolved by the shareholders in their meeting on June 5, 2025 and May 29, 2024, respectively, were as follows:

	<b>Appropriation of Earnings</b>	
	<b>For the Year Ended December 31</b>	
	<b>2024</b>	<b>2023</b>
Legal reserve	<u>\$ 19,222</u>	<u>\$ 16,875</u>
Reversal of special reserve	<u>\$ (27,459)</u>	<u>\$ (16,341)</u>
Cash dividends	<u>\$ 159,497</u>	<u>\$ 152,853</u>
Cash dividends per share (NT\$)	\$ 1.20	\$ 1.15

d. Special reserve

The cumulative translation adjustment transferred to retained earnings was \$8,874 thousand when the Company initially adopted IFRS Accounting Standards. The increase in retained earnings from the initial adoption of IFRS Accounting Standards was not enough to provide for the increase in retained earnings, so only a special reserve of \$1,875 thousand was provided for the increase in retained earnings from the conversion to IFRS Accounting Standards.

e. Other equity items

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
Exchange differences on translation of financial statements of foreign operations attributable to the Company	<u>\$ (24,784)</u>	<u>\$ (13,199)</u>	<u>\$ (14,265)</u>
Unrealized valuation gain (loss) on financial assets at FVTOCI attributable to the Company	(90,682)	(79,560)	(84,270)
Share from associates accounted for using the equity method	<u>19,243</u>	<u>30,397</u>	<u>34,168</u>
	<u>(71,439)</u>	<u>(49,163)</u>	<u>(50,102)</u>
	<u>\$ (96,223)</u>	<u>\$ (62,362)</u>	<u>\$ (64,367)</u>

1) Exchange differences on translation of financial statements of foreign operations

Translation differences arising from the translation of the net assets of foreign operations from their functional currency into the Company's presentation currency (i.e., New Taiwan dollars) are recognized directly in other comprehensive income as translation differences in the financial statements of foreign operations. The cumulative translation differences on the financial statements of foreign operations are transferred to profit or loss upon disposal of the foreign operations.

	<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>
Balance on January 1	<u>\$ (13,199)</u>	<u>\$ (18,070)</u>
Recognized for the period		
Exchange differences on translation of financial statements of foreign operations	<u>(11,585)</u>	<u>3,805</u>
Other comprehensive income recognized for the period	<u>(11,585)</u>	<u>3,805</u>
Balance on June 30	<u>\$ (24,784)</u>	<u>\$ (14,265)</u>

2) Unrealized valuation gain (loss) on financial assets at FVTOCI

	<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>
Balance on January 1	\$ (49,163)	\$ (71,751)
Recognized for the period		
Unrealized gain (loss) equity instruments	(3,754)	9,938
Share from associates accounted for using the equity method	<u>(3,793)</u>	<u>11,711</u>
Other comprehensive income	<u>(7,547)</u>	<u>21,649</u>
Cumulative unrealized gain (loss) of equity instruments transferred to retained earnings due to disposal	<u>(14,729)</u>	<u>-</u>
Balance on June 30	<u>\$ (71,439)</u>	<u>\$ (50,102)</u>

Please refer to Note 28 (b) for the reconciliation of the Level 3 fair value measurements of financial assets at fair value through other comprehensive income.

## 22. REVENUE

	<b>For the Three Months Ended June 30</b>		<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Revenue from contracts with customers				
Revenue from the sale of goods				
Consumer business unit	\$ 253,117	\$ 238,780	\$ 562,589	\$ 534,251
Pharmaceutical business unit	<u>121,536</u>	<u>111,494</u>	<u>234,400</u>	<u>223,724</u>
	<u>\$ 374,653</u>	<u>\$ 350,274</u>	<u>\$ 796,989</u>	<u>\$ 757,975</u>

## Revenue from Sale of Goods

The Group's sales come from various channels, such as e-commerce, medical institutions, wholesalers and retailers, and discounts are granted to different sales targets on different terms. Revenue is measured at the fair value of the consideration received or receivable, less estimated customer returns, discounts and other similar discounts.

## Contract Balances

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>	<b>January 1, 2024</b>
Notes receivable (Note 8)	<u>\$ 15,893</u>	<u>\$ 11,145</u>	<u>\$ 14,983</u>	<u>\$ 22,522</u>
Accounts receivable (Note 8)	<u>\$ 253,215</u>	<u>\$ 239,286</u>	<u>\$ 249,717</u>	<u>\$ 226,268</u>

## 23. NET PROFIT

### a. Interest income

	<b>For the Three Months Ended June 30</b>		<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Bank deposits	<u>\$ 2,315</u>	<u>\$ 2,514</u>	<u>\$ 4,194</u>	<u>\$ 4,332</u>

### b. Other income

	<b>For the Three Months Ended June 30</b>		<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Rental income	\$ 2,720	\$ 2,832	\$ 5,509	\$ 5,618
Dividend income	6,821	5,116	6,821	5,116
Other income	<u>339</u>	<u>1,889</u>	<u>731</u>	<u>2,076</u>
	<u>\$ 9,880</u>	<u>\$ 9,837</u>	<u>\$ 13,061</u>	<u>\$ 12,810</u>

### c. Other gains and losses

	<b>For the Three Months Ended June 30</b>		<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Fair value changes of financial assets				
Financial assets mandatorily classified as at FVTPL	\$ 154	\$ 23	\$ 179	\$ 34
Net foreign exchange gains	<u>440</u>	<u>105</u>	<u>718</u>	<u>398</u>
	<u>\$ 594</u>	<u>\$ 128</u>	<u>\$ 897</u>	<u>\$ 432</u>

d. Interest expense

	<b>For the Three Months Ended June 30</b>		<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Interest on bank loans	\$ 1,924	\$ 1,589	\$ 3,914	\$ 2,835
Interest on lease liabilities	11	6	23	17
Less: Capitalized interest	<u>-</u>	<u>(1,530)</u>	<u>-</u>	<u>(2,776)</u>
	<u>\$ 1,935</u>	<u>\$ 65</u>	<u>\$ 3,937</u>	<u>\$ 76</u>

Information about capitalized interest was as follows:

	<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>
Capitalized interest amount	<u>\$ -</u>	<u>\$ 2,776</u>
Capitalization rate	-	0.68%-1.21%

e. Depreciation and amortization expense

	<b>For the Three Months Ended June 30</b>		<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Analysis of depreciation by function				
Operating costs	\$ 4,471	\$ 3,173	\$ 8,876	\$ 6,840
Operating expenses	<u>8,513</u>	<u>2,901</u>	<u>17,099</u>	<u>6,014</u>
	<u>\$ 12,984</u>	<u>\$ 6,074</u>	<u>\$ 25,975</u>	<u>\$ 12,854</u>
Analysis of amortization by function				
Operating costs	\$ 455	\$ 226	\$ 874	\$ 444
Operating expenses	<u>184</u>	<u>233</u>	<u>353</u>	<u>451</u>
	<u>\$ 639</u>	<u>\$ 459</u>	<u>\$ 1,227</u>	<u>\$ 895</u>

f. Employee benefits expense

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2025	2024	2025	2024
Post-employment benefits (Note 20)				
Defined contribution plan	\$ 1,998	\$ 1,952	\$ 4,109	\$ 3,924
Defined benefit plans	(246)	(92)	(491)	(183)
Other employee benefits				
Salaries and bonuses	47,324	45,682	97,210	92,626
Labor and health insurance	3,946	3,769	8,446	8,069
Others	<u>1,988</u>	<u>1,677</u>	<u>4,009</u>	<u>3,341</u>
Total employee benefits expense	<u>\$ 55,010</u>	<u>\$ 52,988</u>	<u>\$ 113,283</u>	<u>\$ 107,777</u>
Analysis of employee benefits expense by function				
Operating expenses	\$ 42,968	\$ 39,656	\$ 88,870	\$ 83,258
Operating costs	<u>12,042</u>	<u>13,332</u>	<u>24,413</u>	<u>24,519</u>
	<u>\$ 55,010</u>	<u>\$ 52,988</u>	<u>\$ 113,283</u>	<u>\$ 107,777</u>

g. Compensation of employees and remuneration of directors

According to the Company's Articles, the Company accrues compensation of employees and remuneration of directors at rates of 3%-6% and no higher than 4%, respectively, of net profit before income tax, compensation of employees, and remuneration of directors. In accordance with the amendments to the Securities and Exchange Act in August 2024, the shareholders of the Company resolved the amendments to the Company's Articles at their 2025 regular meeting. The amendments explicitly stipulate the allocation of no less than 20% of the compensation of employees in a given year as compensation distributions for non-executive employees. The compensation of employees (including non-executive employees) and the remuneration of directors for the six months ended June 30, 2025 and 2024 are as follows:

Accrual rate

	For the Six Months Ended June 30	
	2025	2024
Compensation of employees	3%	3%
Remuneration of directors	2%	2%

Amount

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2025	2024	2025	2024
	Cash	Cash	Cash	Cash
Compensation of employees	\$ 2,187	\$ 1,858	\$ 4,242	\$ 4,120
Remuneration of directors	1,458	1,239	2,828	2,747

If there is a change in the amounts after the annual consolidated financial statements are authorized for issue, the differences are recorded as a change in the accounting estimate.

The appropriations of employees' compensation and remuneration of directors for 2024 and 2023 that were resolved by the board of directors on February 27, 2025 and February 27, 2024, respectively, are as shown below:

	<u>2024</u>	<u>2023</u>
	Cash	Cash
Compensation of employees	\$ 6,892	\$ 6,639
Remuneration of directors	4,595	4,426

There is no difference between the actual amounts of compensation of employees and remuneration of directors paid and the amounts recognized in the consolidated financial statements for the years ended December 31, 2024 and 2023.

Information on compensation of employees and remuneration of directors resolved by the Company's board of directors is available at the Market Observation Post System website of the Taiwan Stock Exchange.

h. Gains or losses on foreign currency exchange

	<u>For the Three Months Ended</u>		<u>For the Six Months Ended</u>	
	June 30		June 30	
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Foreign exchange gains	\$ 930	\$ 366	\$ 1,344	\$ 726
Foreign exchange losses	<u>(490)</u>	<u>(261)</u>	<u>(626)</u>	<u>(328)</u>
Net gains	<u>\$ 440</u>	<u>\$ 105</u>	<u>\$ 718</u>	<u>\$ 398</u>

## 24. INCOME TAXES RELATING

a. Income tax recognized in profit or loss

Major components of income tax expense (benefit) are as follows:

	<u>For the Three Months Ended</u>		<u>For the Six Months Ended</u>	
	June 30		June 30	
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Current tax				
In respect of the current period	\$ 13,746	\$ 10,098	\$ 31,998	\$ 33,642
Income tax on unappropriated earnings	2,048	-	2,048	-
Adjustments for prior year	807	1,098	(2,019)	(1,127)
Deferred tax				
In respect of the current period	<u>(1,817)</u>	<u>614</u>	<u>(5,239)</u>	<u>(6,902)</u>
Income tax expense recognized in profit or loss	<u>\$ 14,784</u>	<u>\$ 11,810</u>	<u>\$ 26,788</u>	<u>\$ 25,613</u>

b. Income tax assessment

The income tax returns through 2023 have been assessed by the tax authorities, there is no difference between the amount of approved and declared tax.

## 25. EARNINGS PER SHARE

The earnings and weighted average number of ordinary shares outstanding used in the computation of earnings per share were as follows:

### Net Profit for the Period

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2025	2024	2025	2024
Net profit attributable to owners of the Company	<u>\$ 52,464</u>	<u>\$ 46,997</u>	<u>\$ 105,537</u>	<u>\$ 104,832</u>

### Shares

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2025	2024	2025	2024
Weighted average number of ordinary shares used in the computation of basic earnings per share	132,915	132,915	132,915	132,915
Effect of potentially dilutive ordinary shares				
Compensation of employees	<u>194</u>	<u>165</u>	<u>285</u>	<u>250</u>
Weighted average number of ordinary shares used in the computation of diluted earnings per share	<u>133,109</u>	<u>133,080</u>	<u>133,200</u>	<u>133,165</u>

The Group may settle the compensation of employees in cash or shares; therefore, the Group assumes that the entire amount of the compensation will be settled in shares, and the resulting potential shares will be included in the weighted average number of shares outstanding used in the computation of diluted earnings per share, as the effect is dilutive. Such dilutive effect of the potential shares is included in the computation of diluted earnings per share until the number of shares to be distributed to employees is resolved in the following year.

## 26. CASH FLOW INFORMATION

### a. Non-cash transactions

In addition to those disclosed in other notes, the Group entered into the following non-cash investing activities, which were not reflected in the consolidated statements of cash flows for the six months ended June 30, 2025 and 2024:

As of December 31, 2024, the unpaid amount for acquiring property, plant and equipment was \$1,915 thousand, which was recognized in other payables.

As of June 30, 2025 and 2024, the amounts for cash dividends resolved by the shareholders but not yet distributed were \$159,497 thousand and \$152,853 thousand, respectively, which were recognized in other payables (refer to Notes 19 and 21).

### b. Changes in liabilities arising from financing activities

#### For the six months ended June 30, 2025

	Opening Balance	Cash Flows	Non-cash Changes		Closing Balance
			Amortization of Interest	Others	
Short-term borrowings	\$ 35,000	\$ (35,000)	\$ -	\$ -	\$ -
Long-term borrowings	634,464	-	-	-	634,464
Lease liabilities	4,322	(882)	23	(23)	3,440
Guarantee deposits	<u>1,945</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,945</u>
	<u>\$ 675,731</u>	<u>\$ (35,882)</u>	<u>\$ 23</u>	<u>\$ (23)</u>	<u>\$ 639,849</u>

#### For the six months ended June 30, 2024

	Opening Balance	Cash Flows	Non-cash Changes			Closing Balance
			New Leases	Amortization of Interest	Others	
Short-term borrowings	\$ -	\$ 35,000	\$ -	\$ -	\$ -	\$ 35,000
Long-term borrowings	437,893	101,677	-	-	-	539,570
Lease liabilities	4,648	(3,255)	1,025	17	(17)	2,418
Guarantee deposits	<u>1,945</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>1,945</u>
	<u>\$ 444,486</u>	<u>\$ 133,422</u>	<u>\$ 1,025</u>	<u>\$ 17</u>	<u>\$ (17)</u>	<u>\$ 578,933</u>

## 27. CAPITAL RISK MANAGEMENT

The objective of the Group's capital management is to ensure that the companies in the Group can continue to operate, and maximize shareholder returns by optimizing the balance of debt and equity.

The capital structure of the Group consists of net debt (borrowings offset by cash and cash equivalents) and equity attributable to owners of the Group (comprising issued capital, reserves, retained earnings and other equity).

## 28. FINANCIAL INSTRUMENTS

### a. Fair value of financial instruments not measured at fair value

Among the financial assets and financial liabilities not measured at fair value, there is no material difference between the carrying amount and the fair value.

### b. Fair value of financial instruments measured at fair value on a recurring basis

#### 1) Fair value hierarchy

June 30, 2025

	Level 1	Level 2	Level 3	Total
<u>Financial assets at FVTPL</u>				
Mutual funds	\$ 42,000	\$ -	\$ -	\$ 42,000
<u>Financial assets at FVTOCI</u>				
Investments in equity instruments at FVTOCI				
Domestic listed shares	\$ 23,411	\$ -	\$ -	\$ 23,411
Domestic unlisted shares	-	-	78,505	78,505
Foreign unlisted shares	-	-	6,268	6,268
	<u>\$ 23,411</u>	<u>\$ -</u>	<u>\$ 84,773</u>	<u>\$ 108,184</u>

December 31, 2024

	Level 1	Level 2	Level 3	Total
<u>Financial assets at FVTPL</u>				
Mutual funds	\$ 12,000	\$ -	\$ -	\$ 12,000
<u>Financial assets at FVTOCI</u>				
Investments in equity instruments at FVTOCI				
Domestic listed shares	\$ 49,360	\$ -	\$ -	\$ 49,360
Domestic unlisted shares	-	-	79,314	79,314
Foreign unlisted shares	-	-	6,932	6,932
	<u>\$ 49,360</u>	<u>\$ -</u>	<u>\$ 86,246</u>	<u>\$ 135,606</u>

June 30, 2024

	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<u>Financial assets at FVTOCI</u>				
Investments in equity instruments at FVTOCI				
Domestic listed shares	\$ 53,555	\$ -	\$ -	\$ 53,555
Domestic unlisted shares	-	-	76,517	76,517
Foreign unlisted shares	<u>-</u>	<u>-</u>	<u>6,971</u>	<u>6,971</u>
	<u>\$ 53,555</u>	<u>\$ -</u>	<u>\$ 83,488</u>	<u>\$ 137,043</u>

There was no transfer between Level 1 and Level 2 for the six months ended June 30, 2025 and 2024.

2) Reconciliation of Level 3 fair value measurements of financial instruments

Financial assets at FVTOCI - equity instruments

	<b>For the Six Months Ended June 30</b>	
	<b>2025</b>	<b>2024</b>
Balance on January 1	\$ 86,246	\$ 84,581
Recognized in other comprehensive income (included in unrealized valuation gain/(loss) on financial assets at FVTOCI)	<u>(1,473)</u>	<u>(1,093)</u>
Balance on June 30	<u>\$ 84,773</u>	<u>\$ 83,488</u>

3) Level 3 valuation techniques and inputs for measuring fair value

Investments in domestic unlisted equity is calculated by the market approach or asset approach, and the fair value of the investment target is calculated.

In the market approach, the fair value of the investment target is determined based on the transaction price of the stock of companies engaged in similar businesses in the active market, the value multiplier implied by the price, and the discount for lack of marketability.

In the asset approach, the market value of individual assets and liabilities covered by the investment target is used to reflect the value of the business or activities.

c. Categories of financial instruments

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
<u>Financial assets</u>			
Financial assets recognized at FVTPL	\$ 42,000	\$ 12,000	\$ -
Financial assets at amortized cost (Note 1)	899,427	850,970	958,109
Financial assets recognized at FVTOCI			
Equity instruments	108,184	135,606	137,043
<u>Financial liabilities</u>			
Financial liabilities at amortized cost (Note 2)	915,412	962,329	858,555

Note 1: The balances include financial assets at amortized cost, which comprise cash and cash equivalents, notes receivable, accounts receivable, other receivables, other financial assets and refundable deposits.

Note 2: The balances include financial liabilities at amortized cost, which comprise notes payable, accounts payable, other payables (excluding salaries and bonuses payable and dividends payable), long-term borrowings, short-term borrowings and guarantee deposits.

d. Financial risk management objectives and policies

The Group's major financial instruments include equity investments, accounts receivable, other financial assets, accounts payable, borrowings and lease liabilities. The Group's corporate treasury function provides services to the business, coordinates access to domestic and international financial markets, and monitors and manages the financial risks relating to the operations of the Group through internal risk reports that analyze exposures by degree and magnitude of risks. These risks include market risk (including foreign currency risk, interest rate risk and other price risk), credit risk and liquidity.

1) Market risk

The Group's activities exposed it primarily to the financial risks of changes in foreign currency exchange rates and interest rates.

There had been no change to the Group's exposure to market risks or the manner in which these risks were managed and measured.

a) Foreign currency risk

The carrying amounts of the Group's foreign currency denominated monetary assets and monetary liabilities at the end of the reporting period are set out in Note 33.

### Sensitivity analysis

The Group is mainly exposed to the USD and EUR.

The following table details the Group's sensitivity to a 5% increase or decrease in the New Taiwan dollar (the functional currency) against the relevant foreign currencies. The sensitivity rate used when reporting foreign currency risk internally to key management personnel and representing management's assessment of the reasonably possible change in foreign exchange rates is 5%. For a 5% weakening of the New Taiwan dollar against the relevant currency, there would be an equal and opposite impact on pre-tax profit and other equity, and the balances below would be negative (positive).

	<u>USD Impact</u>		<u>EUR Impact</u>	
	<u>For the Six Months Ended</u>		<u>For the Six Months Ended</u>	
	<u>June 30</u>		<u>June 30</u>	
	<u>2025</u>	<u>2024</u>	<u>2025</u>	<u>2024</u>
Profit or loss	\$ (28)	\$ 227	\$ (12)	\$ (72)

The above effects of profit and loss were mainly derived from the Group's foreign currency deposits, accounts receivable and accounts payable valued in the USD and EUR which were still circulating at the balance sheet date.

The Group's exchange rate sensitivity fluctuated compared to the previous period. The Group's sensitivity to USD decreased and EUR decreased respectively during the current period mainly due to a reduction in USD-denominated liabilities and a reduction in EUR-denominated assets.

#### b) Interest rate risk

The carrying amounts of the Group's financial assets and financial liabilities with exposure to interest rates at the end of the reporting period were as follows:

	<u>June 30,</u>	<u>December 31,</u>	<u>June 30,</u>
	<u>2025</u>	<u>2024</u>	<u>2024</u>
Fair value interest rate risk			
Financial assets	\$ 76,909	\$ 128,000	\$ 225,293
Financial liabilities	3,440	4,322	2,418
Cash flow interest rate risk			
Financial assets	545,694	465,358	458,402
Financial liabilities	634,464	669,464	574,570

### Sensitivity analysis

The sensitivity analysis below was determined based on the Group's exposure to interest rates for both derivative and non-derivative instruments at the end of the year. For floating rate liabilities, the analysis was prepared assuming the amount of each liability outstanding at the end of the year was outstanding for the whole year. A 12.5 basis point increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates.

If interest rates had been 12.5 basis points higher/lower and all other variables were held constant, the Group's pre-tax profit for the six months ended June 30, 2025 and 2024 would have increased/decreased by \$(55) thousand and \$(73) thousand, respectively, which was mainly a result of bank deposits and long-term and short-term borrowings.

The Group's sensitivity to interest rates decreased during the current year mainly due to the decrease in net cash flow-generating financial liabilities during the current year.

c) Other price risk

The Group was exposed to equity price risk through its investments in listed or unlisted equity securities.

Sensitivity analysis

The sensitivity analysis below was determined based on the exposure to equity price risks at the end of the period.

If equity prices had been 5% higher/lower, pre-tax profit for the six months ended June 30, 2025 would have increased/decreased by \$2,100 thousand as a result of the changes in fair value of financial assets at FVTPL. Pre-tax other comprehensive income for the six months ended June 30, 2025 and 2024 would have increased/decreased by \$5,409 thousand and \$6,852 thousand, respectively, as a result of the changes in fair value of financial assets at FVTOCI.

The Group's sensitivity to price risk decreased during the current period because of the decrease in equity securities held by the Group.

2) Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group. As the end of the year, the Group's maximum exposure to credit risk, which would cause a financial loss to the Group due to the failure of counterparties to discharge an obligation and due to financial guarantee provided by the Group, could be equal to the total of the carrying amount of the respective recognized financial assets as stated in the balance sheet.

The Group adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, as a means of mitigating the risk of financial loss from defaults.

The Group's accounts receivable cover a wide range of customers in different industries and geographical areas; therefore, the Group does not have significant credit risk to any single counterparty or any group of counterparties with similar characteristics.

3) Liquidity risk

The Group manages liquidity risk by monitoring and maintaining a level of cash and cash equivalents deemed adequate to finance the Group's operations and mitigate the effects of fluctuations in cash flows.

The Group's remaining contractual maturities for its non-derivative financial liabilities with agreed upon repayment periods that have been drawn up based on the undiscounted cash flows of financial liabilities from the earliest date on which the Group can be required to pay include both interest and principal cash flows. Specifically, bank loans with a repayment on demand clause were included in the earliest time band regardless of the probability of the banks choosing to exercise their rights. The maturity dates for other non-derivative financial liabilities were based on the agreed upon repayment dates.

June 30, 2025

	<b>Within 3 Months</b>	<b>3 Months to 1 Year</b>	<b>1-5 Years</b>	<b>5+ Years</b>
<u>Non-derivative financial liabilities</u>				
Non-interest bearing	\$ 279,003	\$ 159,497	\$ 1,945	\$ -
Lease liabilities	500	1,359	1,626	-
Variable interest rate liabilities	<u>3,031</u>	<u>9,092</u>	<u>677,296</u>	<u>-</u>
	<u>\$ 282,534</u>	<u>\$ 169,948</u>	<u>\$ 680,867</u>	<u>\$ -</u>

December 31, 2024

	<b>Within 3 Months</b>	<b>3 Months to 1 Year</b>	<b>1-5 Years</b>	<b>5+ Years</b>
<u>Non-derivative financial liabilities</u>				
Non-interest bearing	\$ 290,920	\$ -	\$ 1,945	\$ -
Lease liabilities	500	1,359	2,532	-
Variable interest rate liabilities	<u>36,920</u>	<u>4,581</u>	<u>545,959</u>	<u>127,398</u>
	<u>\$ 328,340</u>	<u>\$ 5,940</u>	<u>\$ 550,436</u>	<u>\$ 127,398</u>

June 30, 2024

	<b>Within 3 Months</b>	<b>3 Months to 1 Year</b>	<b>1-5 Years</b>	<b>5+ Years</b>
<u>Non-derivative financial liabilities</u>				
Non-interest bearing	\$ 281,985	\$ 152,908	\$ 1,945	\$ -
Lease liabilities	243	587	1,638	-
Variable interest rate liabilities	<u>1,633</u>	<u>4,899</u>	<u>85,088</u>	<u>495,665</u>
	<u>\$ 283,861</u>	<u>\$ 158,394</u>	<u>\$ 88,671</u>	<u>\$ 495,665</u>

Financing facilities

	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
Unsecured bank facilities			
Amount used	\$ -	\$ 35,000	\$ 35,000
Amount unused	<u>-</u>	<u>-</u>	<u>-</u>
	<u>\$ -</u>	<u>\$ 35,000</u>	<u>\$ 35,000</u>
Secured bank facilities			
Amount used	\$ 634,464	\$ 634,464	\$ 539,570
Amount unused	<u>-</u>	<u>51,536</u>	<u>146,430</u>
	<u>\$ 634,464</u>	<u>\$ 686,000</u>	<u>\$ 686,000</u>

**29. TRANSACTIONS WITH RELATED PARTIES**

a. Related parties

<u>Related Party Name</u>	<u>Related Party Category</u>
PhytoHealth Corporation	Investments accounted for using the equity method (associate)
AmCad BioMed Corporation	Investments accounted for using the equity method (associate)
Broadsound Corporation	Investments accounted for using the equity method (associate)
Lu Te Na a Limited	Investments accounted for using the equity method (associate)
Taiwan Incubator SME Development Corp.	The same chairman as the Company (other related parties)

b. Besides information disclosed elsewhere in the other notes, details of transactions between the Group and other related parties are disclosed as follows:

1) Operating transactions

<b>Line Item</b>	<b>Related Party Category</b>	<b>For the Three Months Ended</b>		<b>For the Six Months Ended</b>	
		<b>June 30</b>		<b>June 30</b>	
		<b>2025</b>	<b>2024</b>	<b>2025</b>	<b>2024</b>
Operating revenue	Associates	<u>\$ 285</u>	<u>\$ 2,365</u>	<u>\$ 1,108</u>	<u>\$ 3,632</u>
	Other related parties	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 3</u>	<u>\$ 5</u>

The Group had signed a contract with PhytoHealth Corporation to sell its products. The Group is responsible for sell its promotion business of medicine and health care products. According to the terms of the contract, service will be charged monthly.

Line Item	Related Party Category/Name	For the Three Months Ended		For the Six Months Ended	
		June 30		June 30	
		2025	2024	2025	2024
Operating costs	Purchases of goods				
	PhytoHealth Corporation	<u>\$ 22,835</u>	<u>\$ 27,632</u>	<u>\$ 46,363</u>	<u>\$ 52,130</u>
	Other operation costs associates	<u>\$ 9</u>	<u>\$ 12</u>	<u>\$ 17</u>	<u>\$ 16</u>

The Group had signed a contract with PhytoHealth Corporation to sell its products “PG2® Lyo. Injection”, and other drugs in Taiwan. The contract term is set to start in January 2014 to December 2016. If a party is not notified the contract would not be renewed in writing by the expiration date, and the contract would automatically be renewed for one more year.

The Group had signed a contract with AmCad BioMed Corporation to sell its products “AmCAD-Ute” in Taiwan. The contract term is set to start on April 24, 2015 and end on March 31, 2018. If a party is not notified the contract would not be renewed in writing by the expiration date, and the contract would automatically be renewed for one more year. The Group issued a guarantee note for \$10,000 thousand as collateral of payment.

The purchases and sales prices and payment terms to related parties were not significantly different from those of sales to third parties.

2) Receivables from related parties

Line Item	Related Party Category/Name	June 30, 2025	December 31, 2024	June 30, 2024
Accounts receivable	Associates	<u>\$ -</u>	<u>\$ 24</u>	<u>\$ 1,197</u>
Other receivables	PhytoHealth Corporation	\$ 1,037	\$ 884	\$ 2,113
	AmCad BioMed Corporation	<u>31</u>	<u>36</u>	<u>41</u>
		<u>\$ 1,068</u>	<u>\$ 920</u>	<u>\$ 2,154</u>

The outstanding accounts receivable from related parties are unsecured. For the six months ended June 30, 2025 and 2024, no impairment losses were recognized for accounts receivable from related parties.

Other receivables represent payments made on behalf of the Group.

3) Payables to related parties

<b>Account Item</b>	<b>Related Party Category/Name</b>	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
Accounts payable	PhytoHealth Corporation	\$ 23,977	\$ 19,717	\$ 29,013
	Associates	<u>8</u>	<u>11</u>	<u>13</u>
		<u>\$ 23,985</u>	<u>\$ 19,728</u>	<u>\$ 29,026</u>

4) Refundable deposits

<b>Related Party Category/Name</b>	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
PhytoHealth Corporation	\$ 1,448	\$ 1,448	\$ 1,448
AmCad BioMed Corporation	<u>249</u>	<u>249</u>	<u>249</u>
	<u>\$ 1,697</u>	<u>\$ 1,697</u>	<u>\$ 1,697</u>

The refundable deposits are deposits received from PhytoHealth Corporation and AmCad BioMed Corporation for the rental of a plant and warehouse.

5) Lease arrangements

Lease arrangements - the lessor of the Group under an operating lease

The Group leases the part of the plant to AmCad BioMed Corporation and PhytoHealth Corporation under an operating lease. Part of the lease agreement is specified the lease period will be automatically extended for one year if there are no objections for each other three months prior to the expiration each year.

Lease receivables were as follows:

<b>Related Party Category/Name</b>	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
PhytoHealth Corporation	\$ 551	\$ 551	\$ 551
AmCad BioMed Corporation	<u>85</u>	<u>98</u>	<u>98</u>
	<u>\$ 636</u>	<u>\$ 649</u>	<u>\$ 649</u>

Lease payments to be received in the future were as follows:

<b>Related Party Category/Name</b>	<b>June 30, 2025</b>	<b>December 31, 2024</b>	<b>June 30, 2024</b>
PhytoHealth Corporation	\$ 8,032	\$ 5,591	\$ 8,032
AmCad BioMed Corporation	81	652	141
Lu Te Na Company Limited	<u>-</u>	<u>36</u>	<u>54</u>
	<u>\$ 8,113</u>	<u>\$ 6,279</u>	<u>\$ 8,227</u>

Total lease revenue was as follows:

Related Party Category/Name	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2025	2024	2025	2024
PhytoHealth Corporation	\$ 1,575	\$ 1,575	\$ 3,150	\$ 3,150
AmCad BioMed Corporation	243	279	511	559
Lu Te Na Company Limited	<u>-</u>	<u>9</u>	<u>3</u>	<u>18</u>
	<u>\$ 1,818</u>	<u>\$ 1,863</u>	<u>\$ 3,664</u>	<u>\$ 3,727</u>

The rental amounts and collection methods are similar to that of general leasing transactions.

c. Remuneration of key management personnel

The remuneration of directors and other key management personnel was as follows:

	For the Three Months Ended June 30		For the Six Months Ended June 30	
	2025	2024	2025	2024
Short-term employee benefits	\$ 6,186	\$ 9,848	\$ 15,774	\$ 20,548
Post-employment benefits	<u>35</u>	<u>142</u>	<u>244</u>	<u>284</u>
	<u>\$ 6,221</u>	<u>\$ 9,990</u>	<u>\$ 16,018</u>	<u>\$ 20,832</u>

The remuneration of directors and key executives was determined by the remuneration committee based on the performance of individuals and market trends.

### 30. ASSETS PLEDGED AS COLLATERAL OR FOR SECURITY

The following assets had been pledged as collateral for long-term borrowings:

	June 30, 2025	December 31, 2024	June 30, 2024
Land	\$ 68,149	\$ 74,189	\$ 74,189
Buildings	<u>674,465</u>	<u>741,266</u>	<u>65,445</u>
	<u>\$ 742,614</u>	<u>\$ 815,455</u>	<u>\$ 139,634</u>

### 31. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED COMMITMENTS

In addition to those disclosed in other notes, significant contingencies and unrecognized commitments of the Group were as follows:

As of June 30, 2025, December 31, 2024 and June 30, 2024, the Group issued and deposited guarantee notes as purchase and performance guarantee, both of which are \$10,000 thousand.

### 32. SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD

None.

### 33. SIGNIFICANT ASSETS AND LIABILITIES DENOMINATED IN FOREIGN CURRENCIES

The Group's significant financial assets and liabilities denominated in foreign currencies aggregated by the foreign currencies other than functional currencies of the entities in the Group and the related exchange rates between the foreign currencies and the respective functional currencies were as follows:

(In Thousands of New Taiwan Dollars and Foreign Currencies)

June 30, 2025

	<b>Foreign Currency</b>	<b>Exchange Rate</b>	<b>Carrying Amount</b>
<u>Financial assets</u>			
Monetary items			
USD	\$ 19	29.30 (USD:NTD)	\$ 563
EUR	7	34.35 (EUR:NTD)	234

December 31, 2024

	<b>Foreign Currency</b>	<b>Exchange Rate</b>	<b>Carrying Amount</b>
<u>Financial assets</u>			
Monetary items			
USD	\$ 97	32.79 (USD:NTD)	\$ 3,172
JPY	3,005	0.21 (JPY:NTD)	631
EUR	73	34.14 (EUR:NTD)	2,499
<u>Financial liabilities</u>			
Monetary items			
USD	107	32.79 (USD:NTD)	3,517
JPY	4,505	0.21 (JPY:NTD)	945
EUR	74	34.14 (EUR:NTD)	2,531

June 30, 2024

	<b>Foreign Currency</b>	<b>Exchange Rate</b>	<b>Carrying Amount</b>
<u>Financial assets</u>			
Monetary items			
USD	\$ 67	32.45 (USD:NTD)	\$ 2,161
EUR	41	34.71 (EUR:NTD)	1,436
<u>Financial liabilities</u>			
Monetary items			
USD	206	32.45 (USD:NTD)	6,693

Refer to Note 23 (h) for the foreign currency exchange gains and losses (realized and unrealized) of the Group for the six months ended June 30, 2025 and 2024. Due to the wide variety of foreign currency transactions, it is impractical to disclose the exchange gains and losses for each foreign currency.

### **34. SEPARATELY DISCLOSED ITEMS**

a. Information on significant transactions:

- 1) Financing provided to others: None;
- 2) Endorsements/guarantees provided: None;
- 3) Marketable securities held (excluding investments in subsidiaries, associates and joint ventures): (Table 1);
- 4) Total purchases from or sales to related parties amounting to at least NT\$100 million or 20% of the paid-in capital: None;
- 5) Receivables from related parties amounting to at least NT\$100 million or 20% of the paid-in capital: None;
- 6) Others: Intercompany relationships and significant intercompany transactions: (Table 4)

b. Information on investees (Table 2)

c. Information on investments in mainland China

- 1) Information on any investee company in mainland China, showing the name, principal business activities, paid-in capital, method of investment, inward and outward remittance of funds, ownership percentage, investment income or loss, carrying amount of the investment at the end of the year, repatriations of investment income, and limit on the amount of investment in the mainland China area (Table 3)
- 2) Any of the following significant transactions with investee companies in mainland China, either directly or indirectly through a third party, and their prices, payment terms, and unrealized gains or losses:
  - a) The amount and percentage of purchases and the balance and percentage of the related payables at the end of the year: None.

- b) The amount and percentage of sales and the balance and percentage of the related receivables at the end of the year: Table 3
- c) The amount of property transactions and the amount of the resultant gains or losses: None.
- d) The balance of negotiable instrument endorsements or guarantees or pledges of collateral at the end of the year and the purposes: None.
- e) The highest balance, the ending balance, the interest rate range, and total current period interest with respect to the financing of funds: None.
- f) Other transactions that have a material effect on the profit or loss for the year or on the financial position, such as the rendering or receipt of services: None.

### 35. SEGMENT INFORMATION

Information reported to the Group's chief operating decision maker for the purpose of resource allocation and assessment of segment performance focuses on the type of goods or services delivered or provided. The reporting departments of the Group are as follows: Management Department, Consumer Business Department, and Pharmaceutical Business Department.

#### a. Segment revenue and results

The following was an analysis of the Group's revenue and results from continuing operations by reportable segments:

	Segment Income		Segment Gain/Loss	
	For the Six Months Ended		For the Six Months Ended	
	June 30		June 30	
	2025	2024	2025	2024
Consumer business unit	\$ 562,589	\$ 534,251	\$ 108,047	\$ 122,209
Pharmaceutical business unit	<u>234,400</u>	<u>223,724</u>	<u>65,374</u>	<u>52,708</u>
	<u>\$ 796,989</u>	<u>\$ 757,975</u>	175,421	174,917
Inseparable management expense (including other revenue and expenses, net)			(46,445)	(51,506)
Interest income			4,194	4,332
Rental income			5,509	5,618
Dividend income			6,821	5,116
Other income			731	2,076
Gain on financial assets at fair value through profit or loss			179	34
Foreign exchange gains, net			718	398
Interest expenses			(3,937)	(76)
Share of loss of associates			<u>(8,866)</u>	<u>(10,464)</u>
Profit before taxes (continuing operations)			<u>\$ 132,325</u>	<u>\$ 130,445</u>

Segment revenue reported above represents revenue generated from external customers. There were no intersegment sales for the six months ended June 30, 2025 and 2024.

Segment profit represented the profit before tax earned by each segment without interest income, rental income, other income, foreign currency exchange gains, gain of financial assets at fair value through profit or loss, interest expense and share of profit or loss of associates accounted for using the equity method. This measured amount was reported to the chief operating decision maker for the purpose of resource allocation and assessment of segment performance.

b. Segment assets

The Group had not reported segment assets and liabilities information to the chief operating decision maker. Thus, no disclosure is made.

**MAYWUFA COMPANY LTD. AND SUBSIDIARIES**

**MARKETABLE SECURITIES HELD (EXCLUDING INVESTMENTS IN SUBSIDIARIES)  
FOR THE SIX MONTHS ENDED JUNE 30, 2025  
(Amounts in Thousands of New Taiwan Dollars)**

Holding Company Name	Marketable Securities Type and Name	Relationship with the Company	Financial Statement Account	June 30, 2025				Note
				Shares/Units (In Thousands)	Carrying Amount	Percentage of Ownership (%)	Fair Value (Note 1)	
Maywufa Company Ltd.	<u>Share</u> Cathay Financial Holdings Co., Ltd.	-	Financial assets at fair value through other comprehensive income	253	\$ 15,885	-	\$ 15,885	Listed shares
	Fubon Financial Holding Co., Ltd.	-	Financial assets at fair value through other comprehensive income	86	7,526	-	7,526	Listed shares
	Taiwan Incubator SME Development Corp.	Same chairman	Financial assets at fair value through other comprehensive income	8,526	70,938	12.08	70,938	
	Miho International Cosmetic Co., Ltd.	-	Financial assets at fair value through other comprehensive income	333	-	0.39	-	
	Career Consulting Co., Ltd.	-	Financial assets at fair value through other comprehensive income	505	7,351	3.23	7,351	
	Amersen Bioscience International, Inc.	-	Financial assets at fair value through other comprehensive income	568	-	8.43	-	
	Biowell Technology, Inc.	-	Financial assets at fair value through other comprehensive income	3,272	-	7.56	-	
	WS Fashion Group Co., Ltd.	-	Financial assets at fair value through other comprehensive income	13	216	0.38	216	
	Amkey Biotechnology Venture Capital Inc.	-	Financial assets at fair value through other comprehensive income	147	6,268	6.66	6,268	
	<u>Fund</u> Capital Money Market Fund	-	Financial assets at fair value through profit or loss	2,478	42,000	-	42,000	

Note 1: Reference of fair value: listed (over the counter) stocks of financial assets measured by fair value through other comprehensive income are the closing prices at the end of June 2025, and unlisted (over the counter) stocks are estimated market prices based on the fair value evaluation method.

Note 2: For information of subsidiaries, refer to Tables 2 and 3.

## MAYWUFA COMPANY LTD. AND SUBSIDIARIES

INFORMATION ON INVESTEEES  
FOR THE SIX MONTHS ENDED JUNE 30, 2025  
(Amounts in Thousands of New Taiwan Dollars, Unless Specified Otherwise)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of June 30, 2025			Net Income (Loss) of the Investee	Share of Profit (Loss) (Note 1)	Note
				June 30, 2025	December 31, 2024	Shares (In Thousands)	%	Carrying Amount			
Maywufa Company Ltd.	<u>Related company</u> PhytoHealth Corporation	Fuxing N. Rd., Taipei City, Taiwan (R.O.C.)	Pharmaceutical research and development, production, manufacturing and sales	\$ 1,019,037	\$ 1,016,963	35,277	17.76	\$ 445,009	\$ (36,443)	\$ (5,620)	
	AmCad BioMed Corporation	Fuxing N. Rd., Taipei City, Taiwan (R.O.C.)	Medical materials and equipment manufacturing	77,737	77,737	3,995	6.31	33,477	(31,690)	(1,979)	
	Broadsound Corporation	Xintai Rd., Zhubei City, Taiwan (R.O.C.)	Medical materials and equipment manufacturing	26,360	26,360	2,019	10.00	21,605	(11,717)	(1,281)	
	Lu Te Na Company Limited	Fuxing N. Rd., Taipei City, Taiwan (R.O.C.)	Cosmetics sales	7,000	7,000	700	35.00	2,343	39	14	Dissolution and liquidation
	<u>Subsidiaries</u> Maywufa Corporation	Vistra Corporate Services Centre, Ground Floor NPF Building, Beach Road, Apia, Samoa	Investment	US\$ 8,500	US\$ 8,500	8,500	100.00	126,466	(2,610)	(2,610)	(Note 2)
Maywufa Corporation	Maywufa Hongkong Corporation Limited	Room 06, G/F, 535 Canton Road, Kowloon, Hong Kong	Investment	US\$ 8,500	US\$ 8,500	8,500	100.00	127,253	(2,610)	(2,610)	(Note 2)
Maywufa Hongkong Corporation Limited	Maywufa Cosmetics (Shanghai) Co., Ltd.	Room 902, No. 777, Hongqiao Road, Xuhui District, Shanghai	Cosmetics and household goods wholesale	US\$ 7,500	US\$ 7,500	-	100.00	127,250	(2,610)	(2,610)	(Note 2)

Note 1: Recognition of investment gains (losses) was based on the investee's reviewed financial statements.

Note 2: The amounts have been eliminated from the consolidated financial statements.

Note 3: For the information on investment in mainland China, refer to Table 3.

## MAYWUFA COMPANY LTD. AND SUBSIDIARIES

INFORMATION ON INVESTMENTS IN MAINLAND CHINA  
FOR THE SIX MONTHS ENDED JUNE 30, 2025  
(Amounts in Thousands of New Taiwan Dollars and US Dollars)

1. Name of the investee company in mainland China, main businesses, paid-in capital, investment method, capital remittance, shareholding ratio, investment profit and loss, book value of investment at the end of the period, and repatriated investment profit and loss were as follow:

Investee Company	Main Businesses and Products	Paid-in Capital	Method of Investment	Accumulated Outward Remittance for Investment from Taiwan as of January 1, 2025	Remittance of Funds		Accumulated Outward Remittance for Investment from Taiwan as of June 30, 2025	Net Income (Loss) of the Investee	% Ownership of Direct or Indirect Investment	Accumulated Repatriation of Investment Income as of June 30, 2025	Carrying Amount as of June 30, 2025	Accumulated Inward Remittance for Investment from Taiwan as of June 30, 2025
					Outward	Inward						
Maywufa Cosmetics (Shanghai) Co., Ltd.	Cosmetics and household goods wholesale	\$ 226,459 (US\$ 7,500)	Reinvesting in mainland China through companies located in a third region (Note 1)	\$ 226,459 (US\$ 7,500)	\$ -	\$ -	\$ 226,459 (US\$ 7,500)	\$ (2,610)	100	\$ (2,610) (Note 2)	\$ 127,250	\$ -

Note 1: The Company located in a third region is Maywufa Hongkong Corporation Limited.

Note 2: Investment gains and losses are recognized according to the financial statements reviewed by the accountant.

2. Investment limit in mainland China

(Amounts in Thousands of New Taiwan Dollars and US Dollars)

Accumulated Outward Remittance for Investments in Mainland China as of June 30, 2025	Investment Amount Authorized by the Investment Commission, MOEA	Upper Limit on the Amount of Investments Stipulated by the Investment Commission, MOEA
\$226,459 (US\$7,500)	\$322,300 (US\$11,000)	\$1,220,267

Note: Upper Limit on the Amount of Investments Stipulated by the Investment Commission, MOEA = \$2,033,778 × 60% = \$1,220,267.

3. The significant transactions with investee companies in mainland China either directly or indirectly through a third party

Investee Company	Relationship with the Company	Transaction Type	Price	Transaction Details			Notes/Accounts Receivable (Payable)		Unrealized Gain (Loss)
				Price	Payment Terms	Comparison with Normal Transactions	Ending Balance	%	
Maywufa Cosmetics (Shanghai) Co., Ltd.	Subsidiary	Sales revenue	\$ 7,411	Determined by contract or negotiation	The credit period for hairdressing products is 3 months	Similar to general transaction	\$ -	-	\$ 788

4. Endorsements, guarantees or collateral provided to mainland investment companies directly or indirectly through companies in a third region: None.
5. Direct and indirect financing with mainland investment companies via third regions: None.
6. Other transactions that have a significant impact on the current profit or loss or financial position: None.
7. When preparing the consolidated financial statements, the above transactions have been eliminated.

**MAYWUFA COMPANY LTD. AND SUBSIDIARIES**

**INTERCOMPANY RELATIONSHIPS AND SIGNIFICANT INTERCOMPANY TRANSACTIONS  
FOR SIX MONTHS ENDED JUNE 30, 2025  
(Amounts in Thousands of New Taiwan Dollars)**

No.	Investee Company	Counterparty	Relationship	Transactions Details			
				Financial Statement Account	Amount (Note 1)	Payment Terms	% of Total Sales or Assets (Note 2)
0	Maywufa Company Ltd.	Maywufa Cosmetics (Shanghai) Co., Ltd.	Parent company to subsidiary	Operating income	\$ 7,411	Similar to general transaction	-

Note 1: The table only shows one-way transactions, and the transactions have been eliminated.

Note 2: The calculation of the ratio of the transaction amount to the consolidated total revenue or total assets: If it is an asset - liability account, it is calculated as the ending balance of the consolidated total assets; if it is a profit and loss account, it is calculated as the cumulative amount to the consolidated total revenue.